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Abstract 
 
Recent research has suggested that neurofeedback, utilising alpha asymmetry or fractal dimension as 
an index of depression, may be an effective treatment for depressed individuals. In this thesis the 
relationships between frontal alpha asymmetry (FAA), parietal alpha asymmetry (PAA) and Higuchi’s 
fractal dimension (HFD) with PID-5 depressivity were investigated to assess their potential as signals 
for neurofeedback. Resting EEG previously recorded from a general sample of 66 individuals was 
analysed.  The data of male and female participants was analysed separately.  Optimised eye condition 
and bandwidth were determined with one way, repeated measure ANOVAs. Optimal specific 
measures of FAA, PAA and HFD were then identified by the proportion of PID-5 depressivity 
accounted for. The optimal FAA measure was obtained from the frontopolar electrode pair (Fp2 – 
Fp1) in the 10-12Hz sub-band. It was the only measure that was reliable in both male and female 
participants. PAA between the lateral electrode pair (P8 – P7) in the 8-10hz sub-band reliably 
correlated with depressivity in female, but not male, participants. HFD was reliable at every electrode 
in female, but not male, participants and displayed intercorrelation between all electrodes in both 
genders. A combined model using all three optimal measures showed that the proportional variance of 
FAA, PAA and HFD was mainly additive, with little variance shared between measures. The results 
suggest that FAA at the frontopolar electrode pair (Fp2 – Fp1) in the 10 – 12Hz band may be the 
optimal AA measure for neurofeedback protocols targeting depression. Correlations between AA and 
depressivity were often site- and band-specific; reliable correlations observed in one location did not 
necessarily generalise to other locations. Correlations between HFD and depressivity were not site-
specific with most variance shared between sites. There was little overlap between the variance 
accounted for by FAA, PAA and HFD; indicating that the information conveyed by each is due to 
distinct neural processes, which may be associated with distinct aspects of depressivity and, 
potentially, other trait measures. Future work should assess replicability and the extent to which the 
results are specific to depressivity.  
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CHAPTER 1: INTRODUCTION 
 
Overview of Depression 
 Depressive illnesses are one of the most common mental health disorders. Depression is now 
the leading cause of disability in the world (WHO, 2017). It has a 12-month prevalence in New 
Zealand of over 5% (Oakley-Browne, Wells, & Scott, 2006). It is characterized by negative mood, loss 
of pleasure, decreased quality of life, suicide risk, and poor prognosis. Millions are affected annually 
around the world with consequences that extend past the individual to families, communities, and the 
economy. The mainstream treatments that are available often fail to adequately treat depressive 
symptoms and produce undesirable side-effects. It is critical that we identify depression-specific 
biomarkers that can be used as a benchmark to identify response to treatments, improve diagnosis and 
assist in the development of new or improved treatments. Current attempts at identifying promising 
electrophysiological biomarkers of depression have met with mixed results (Allen & Reznik, 2015; 
Debener et al., 2000) but suggest that the alpha wave band has some relationship to depression. 
Neurofeedback protocols train individuals to alter alpha power in the brain; and recent research 
suggests this may be a promising self-administered treatment for depression (Peeters, Ronner, Bodar, 
van Os, & Lousberg, 2014; Wang et al., 2016). The primary aim of this thesis is to identify the best 
frontal alpha asymmetry measure for use in neurofeedback protocols.  
 
Defining depression 
Major depressive disorder (MDD) is a mood disorder characterised by negative mood, loss of 
pleasure, decreased quality of life, suicide risk, poor prognosis and can also include weight changes, 
insomnia/hypersomnia, psychomotor agitation/retardation, fatigue, feelings of worthlessness and guilt, 
diminished cognitive abilities and recurrent thoughts of death/suicide (American Psychiatric 
Association, 2013). MDD is thought to afflict over 4% of the global population at any given point in 
time, which suggests that at this moment 300 million people are suffering from MDD (Ferrari et al., 
2013). The percentage of mild MDD cases (10.4%) is drastically overshadowed by moderate (38.6%), 
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severe (38.0%) and very severe (12.9%) cases (Kessler et al., 2003). These findings show a top-heavy 
distribution of symptom severity with over 50% of MDD sufferers experiencing severe symptoms. 
MDD brings with it significant costs at both the economic and individual level.  
Depressive mental illnesses are diverse in both symptomatology and expression. The 
Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5; American Psychiatric 
Association, 2013) provides diagnostic information for a multitude of different depressive disorders 
and subtypes. The benefit of having such a wide variety of diagnoses is that people suffering from 
uncommon forms of depressive symptoms are more likely to be diagnosed and treated. From a clinical 
perspective, this grouping of symptom clusters that are treated similarly is useful because it allows for 
simplified diagnosis and treatment. From a research perspective, there is a question to be asked: How 
broad a definition is too broad?  
 The utility of the broad diagnoses seen in depression, particularly in Major Depressive 
Disorder (MDD), has been questioned in recent years. There are at least 170 different ways patients 
meet the criteria for a diagnosis of MDD (Zimmerman, Ellison, Young, Chelminski, & Dalrymple, 
2015) with this number theoretically being as high as 1497 (Ostergaard, Jensen, & Bech, 2011). While 
these combinations have depressed mood in common, for many patients this will be where the 
similarity ends; with distinct symptom profiles being the norm (Fried & Nesse, 2015). The 
heterogeneity of MDD and the failure of treatment to help a significant proportion of patients 
(Ostergaard et al., 2011) suggest that progress in this domain requires a careful reappraisal of the 
dominant view of depression as a natural kind (Fried, 2015).  
 
Somatic effects of depression 
There is considerable evidence of depression acting as a risk factor for cardiovascular-related 
diseases (CVD; Goldston & Baillie, 2008; Holt et al., 2013; Kuper et al., 2009; Lett, 2004; Rudisch & 
Nemeroff, 2003; Rugulies, 2002). Support for this is strong, with powerful effects observable in a 
cohort of over 1.9 million individuals (Daskalopoulou et al., 2016). Depression increases the 
Page - 3 
likelihood of adverse outcomes and mortality in CVD (Barth, Schumacher, & Herrmann-Lingen, 
2004; Freedland & Carney, 2013; Rudisch & Nemeroff, 2003). MDD is estimated to be responsible 
for 3% of ischemic heart disease’s disability adjusted life years (DALY) burden (Charlson et al., 
2013). 
The increased risk of cardiovascular diseases may be partially attributable to a connection 
between depression and metabolic syndrome (MetS). MetS refers to a cluster of metabolic factors 
which directly increase the risk of CVD, type 2 diabetes and all-cause mortality (Kaur, 2014). These 
factors include obesity, hyperglycaemia, elevated blood pressure, increased triglycerides and 
decreased HDL cholesterol (Penninx, Milaneschi, Lamers, & Vogelzangs, 2013).  There is a wealth of 
research that has found an increase of MetS prevalence in depressed populations (Kahl et al., 2012; 
Seppala et al., 2012; Vancampfort et al., 2014). The relationship appears to be bi-directional (Pan et 
al., 2012) and the combination of both MetS and depressive symptoms appears to confer an additive 
risk for type 2 diabetes (Schmitz et al., 2016) and CVD (Vaccarino et al., 2008). Recent evidence also 
suggests that antidepressant use may increase likelihood of occurrence and worsen pre-existing MetS 
(Corruble et al., 2015; Crichton, Elias, & Robbins, 2016; Hiles, Revesz, Lamers, Giltay, & Penninx, 
2016).  
As with cardiovascular disease, a history of depression also confers an added risk for future 
dementia. In the case of Alzheimer’s disease, a history of depression increases the odds of 
development, even when the onset of depression is decades prior to the Alzheimer’s disease 
(Geerlings, den Heijer, Koudstaal, Hofman, & Breteler, 2008; Green et al., 2003). Early onset 
depression may also be a risk factor for dementias in general (Simoes do Couto et al., 2016). The 
relationship between depression and dementia isn’t entirely clear with evidence that depression may 
be a prodrome and a risk factor depending on time of onset (Late vs. early onset; da Silva, Goncalves-
Pereira, Xavier, & Mukaetova-Ladinska, 2013). Depression is known to involve reductions in brain 
volume, particularly in the hippocampus and amygdala (Schmaal et al., 2016) with longer periods of 
depression corresponding to greater decreases in hippocampal volume (Buddeke et al., 2017).This 
pattern of decreased hippocampal volume is also a distinguishing feature of Alzheimer’s disease (den 
Heijer et al., 2006). 
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Suicide 
Depressive disorders of any kind have very serious and deadly effects on the physical health 
of those affected. Suicide, the taking of one’s own life, is a common behaviour in depression. The 
suicide rate for affective disorders is thought to be 6% (Inskip, Harris, & Barraclough, 1998). 
Longitudinal data shows that severity correlates with differences in suicide rates. 3.1% of moderate 
and 13.7% of severe MDD patients attempt suicide (Bradvik, Mattisson, Bogren, & Nettelbladt, 2008). 
This dose-dependent relationship between suicide and depression severity is of great concern as over 
50% of MDD sufferers are in the severe range of MDD (Kessler et al., 2003).  
 
Global Cost of MDD 
The economic cost of depressive illnesses is massive. The 2010 Global burden of disease 
study (Ferrari et al., 2013) ranked MDD as the second largest contributor to years of healthy life lost 
due to disability (YLD) and 11th highest contributor to DALYs globally. This burden is higher in New 
Zealand with MDD ranking as 4th in Australasia for DALY’s (Ferrari et al., 2013). It should come as 
no surprise that this scale of disability comes with a large economic burden. A 2011 report from the 
World Economic Forum placed the estimated economic cost of mental illness at $2.5 trillion U.S 
dollars in 2010 (Bloom et al., 2011) and is expected to rise to $6 trillion by 2030. Reduced efficiency 
and absenteeism due to MDD have been reported to cost U.S. businesses up to $36 billion annually 
(Kessler et al., 2006). A study investigating the cost of chronic conditions to DOW Chemicals 
Company found that individuals with a primary health condition of depression or anxiety cost the 
company $15,000 per year in decreased productivity (Collins et al., 2005). An Australian study found 
that compared to healthy controls depressed employees cost between $1,620 and $3,900 extra in lost 
productivity; with an estimated $8 billion total loss in Australia as a result (McTernan, Dollard, & 
LaMontagne, 2013). The economic costs of depressive illnesses are enormous and presents a prime 
target for cost-effective intervention and prevention.  
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The Current State of Treatment and Barriers to Access 
The primary methods of treating MDD are pharmacological and psychological. 
Pharmacological treatment is the prescription of antidepressant medications, this kind of treatment 
takes place through either a licenced psychiatrist or general practitioner. Psychological treatment is 
administrated through a clinical psychologist. Behavioural and cognitive techniques are used to assist 
the patient in recovering and managing their depressive symptoms. Often these methods are applied in 
conjunction with each other. Each has distinct benefits, consequences and barriers to access.  
 
Pharmacological management 
There are many types of antidepressant medication. The oldest classes of antidepressants are 
monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs).  The inhibition of 
monoamine oxidase by MAOIs results in increased levels of monoamines including serotonin, 
norepinephrine and dopamine. MAOIs are particularly dangerous as their inhibition of monoamine 
breakdown means that the consumption of anything that boosts monoamine levels can result in 
toxicity (Riederer, Lachenmayer, & Laux, 2004).  TCAs inhibit the reuptake of serotonin and 
norepinephrine from the synaptic cleft and so increase levels but through a different mechanism than 
MAOIs and, importantly, with much less dangerous side effects. Newer classes of antidepressants 
include serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake 
inhibitors (SSRIs). SNRI’s inhibit the reuptake of both serotonin and norepinephrine, while SSRIs 
inhibit the reuptake of serotonin.  These newer classes have similar efficacy to MAOIs and TCAs, but 
are much better tolerated. In all classes of antidepressants, the focus is set on increasing the 
bioavailability of monoamines, primarily serotonin and norepinephrine (Ruhe, Mason, & Schene, 
2007). 
 
Prescribing practices  
The pharmacological management of depression in New Zealand appears to be based on the 
work of Thase and Rush (1997) in which the authors proposed a staging model for determining 
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treatment-resistance and a method of prescription for depression. Thase and Rush (1997) proposed 
beginning with SSRI monotherapy then progressively moving on to other classes (SNRI, TCA and 
MAOI) if each subsequent treatment is ineffective after 4-6 weeks with the final option being electro-
convulsive therapy (ECT). This progression follows the tolerability of the different drugs, starting with 
the most tolerable (SSRIs) as the first step. At each stage, the possibility of increasing dosage, 
switching within class and augmentation are also presented. The Best Practice Advocacy Centre New 
Zealand (BPACNZ, 2009) suggests a second SSRI be used if a first fails. New Zealand clinical 
guidelines for management after this point are detailed by Ellis and Royal Australian and New 
Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression (2004), which 
follows a similar trajectory as Thase and Rush (1997) though is much more detailed.  
 
Efficacy of pharmacological management  
The efficacy of antidepressant drugs is a topic that has received a lot of attention. The largest 
antidepressant medication trial conducted thus far is the Sequenced Treatment Alternatives to Relieve 
Depression (STAR*D) trial (Gaynes et al., 2008).The study investigated the efficacy of antidepressant 
medications in a sample of 4041 outpatients. The study used 4 sequential levels of treatment. Patients 
who responded to treatment at any level could remain on the effective medication, while the others 
were given the option of moving onto the next level of the trial. Reported results were promising with 
cumulative remission rates of 33% at level 1, 50% after 2 level, 60% after 3 levels and 70% after the 
4th level of the trial (Warden, Rush, Trivedi, Fava, & Wisniewski, 2007).  
A detailed analysis of the research methods applied in the STAR*D trial reveals some points 
of concern. The cumulative remission rates were calculated from one of the study’s secondary 
measures and not the primary outcome measure (Hamilton Rating Scale for Depression; HRSD) 
discussed in the studies design (Rush et al., 2004). This appears to have resulted in inflated remission 
rates (Pigott, Leventhal, Alter, & Boren, 2010). There is evidence of a series of rounding errors which 
resulted in a steady increase in reported efficacy (Pigott, 2011). The reported cumulative remission 
rates assume that if those who dropped out had remained in the study they would have responded at 
the same rate as those who stayed (Rush et al., 2006). However, it had been previously stated that 
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patients with missing HRSD scores on exit would be considered as non-remitters, a priori (Trivedi et 
al., 2006). Application of that criterion would have resulted in a cumulative response rate of 37.6% 
(1,518 out of 4,041 patients; Pigott et al., 2010), instead of the claimed 70%. 
There are other barriers to determining the efficacy of antidepressants. The difference between 
placebo and active treatment is a topic of significant debate. The work of Kirsch et al. (2008) found 
antidepressants were only significantly better than placebo for very severe MDD patients. Later 
reanalysis of the same data set suggests that the difference between placebo and antidepressants is 5% 
for mild, 12% for moderate and 16% for severe MDD (Vohringer & Ghaemi, 2011). Another issue is 
the rate of spontaneous recovery. The proportion of untreated depression cases that remit within 12 
months is predicted to be as high as 53% (Whiteford et al., 2013). The rates of spontaneous remission 
appear to be much lower in treatment-resistant populations with 3.6% remitting with a 12 month 
period (Dunner et al., 2006).  
Overall, the current research is in favour of antidepressants having a significant benefit in 
cases of moderate and severe MDD, although the placebo effect does account for a sizable proportion 
of the total effect. The benefit of antidepressant treatment is dependent upon the severity of depression 
with more severe cases having a higher rate of response to the treatment.  
 
Psychotherapeutic approaches 
Psychotherapy aims to treat mental illness using psychological rather than medical means. 
Research on the efficacy of psychotherapies is extensive, Cognitive Behavioural Therapy (CBT) is the 
most widely evidenced form of psychotherapy. In the interest of simplicity this discussion will focus 
on CBT exclusively; due in part to the prevalence of research assessing its efficacy but also because 
differences between types of psychotherapy are often minor (Cuijpers, van Straten, Andersson, & van 
Oppen, 2008; Tolin, 2010), even when compared to newer types like metacognitive therapy (Jordan et 
al., 2014). CBT is focused on imparting cognitive and behavioural skills that patients can use to 
manage their symptoms. Parts of this therapy often include the patient being taught about the cognitive 
model of depression, learning to identify and challenge their own thought processes and altering 
Page - 8 
behaviour patterns (Enright, 1997). CBT is often used in the treatment of mood disorders, especially 
depression and anxiety (Cuijpers, Cristea, Karyotaki, Reijnders, & Huibers, 2016). 
 
Efficacy of CBT and CBT plus drugs  
The differences between different kinds of psychotherapy may be small (Barth et al., 2004) 
but favours CBT as the most effective psychotherapy for depression and anxiety (Tolin, 2010). The 
efficacy of CBT in treating MDD is small to moderate (Barth et al., 2013; Butler, Chapman, Forman, 
& Beck, 2006; Dubicka et al., 2010; Furukawa et al., 2017). This is comparable to that of 
pharmacological treatment with antidepressants (Karyotaki et al., 2016; Roshanaei-Moghaddam et al., 
2011; Wiles et al., 2013).  
Pharmacotherapy and CBT are often used in combination to treat MDD. The use of this 
combined therapy improves the overall efficacy of treatment (Barth et al., 2013; Karyotaki et al., 
2016; Thase, 2007; Wiles et al., 2013) although this may not hold equally across severities (de Maat, 
Dekker, Schoevers, & de Jonghe, 2007). Patients who undergo CBT seem to have a reduced rate of 
relapse compared to pharmacotherapy (Beshai, Dobson, Bockting, & Quigley, 2011; Vittengl, Clark, 
Dunn, & Jarrett, 2007). MDD has a relapse rate of 33.5% to 50% (Warden et al., 2007), which makes 
any reduction in relapse rate highly desirable.  
The effectiveness of CBT, both alone and in combination with pharmacotherapy, make it a 
valuable tool for treating MDD. CBT has the added benefit of avoiding the side effect profiles that 
come with pharmacotherapy while maintaining a similar level of efficacy. Overall combined therapy is 
the optimal method for treating depression effectively. 
  
Barriers and problems associated with pharmacotherapy and CBT 
 
The efficacy of pharmacotherapy and psychotherapy are not the only important factors in the 
treatment of MDD. The ability and willingness of patients to engage with treatment is of critical 
importance. There are a wide range of barriers to engaging effectively with mental health care. The 
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most obstructive of these appear to be attitudinal barriers such as patients desire to handle the problem 
on their own, perceived ineffectiveness of treatment, and stigma. There are also structural barriers 
such as financial cost (Andrade et al., 2014). 
Depression is, by nature, at odds with treatment-seeking behaviour. Seeking treatment requires 
that the patient be motivated to actively seek out and engage with mental health professionals, to keep 
scheduled appointments, and interact socially and be open with unfamiliar people. These things are in 
stark contrast to the withdrawn and internalising behaviours that characterise depression. It follows 
naturally that there will be significant barriers to treatment associated with this conflict. The desire to 
handle the problem themselves (Andrade et al., 2014) and the reduced perceived need for treatment 
(Mohr et al., 2010) are likely to be symptoms of this issue. These problems are compounded by 
perceptions of social and economic stigma that come with diagnostic labelling.  
Health care of any kind is rarely cheap, mental health care is no exception to this. The 
financial cost of treatment functions as a structural barrier to accessing mental health care with 
household income having a significant correlation to seeking treatment (Carragher, Adamson, 
Bunting, & McCann, 2010; Simon, Fleck, Lucas, Bushnell, & Group, 2004). Self-reported barriers to 
treatment also show financial cost as being a major issue (Andrade et al., 2014). The cost effectiveness 
of CBT and pharmacotherapy is acceptable at a governmental level (Hollinghurst et al., 2014; Vos, 
Corry, Haby, Carter, & Andrews, 2005). Improved investment into mental health care is likely to bring 
with it significant long term returns (Chisholm et al., 2016). Unfortunately, even in countries with 
well-funded mental health systems access to mental health care is still limited by income (Steele, 
Glazier, & Lin, 2006).  
  Overcoming these barriers is difficult as many of the issues are fundamental in nature. The 
financial cost of treatment to the individual can be lowered through government funding, though this is 
redistribution of costs and not a true reduction. Engaging with mental health professionals will always 
require motivation on behalf of the individual and some element of social interaction. An alternative 
possibility is to work with these barriers instead of against them. The development of tools such a 
neurofeedback offers this possibility.  
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Neurofeedback as a Possible Treatment Method 
 Neurofeedback is a method that may be useful in treating depression and navigating some of 
the barriers to traditional treatments. Neurofeedback protocols use the electroencephalogram (EEG) to 
monitor specific aspects of cortical activity and relays that information back to the participant. The 
subject attempts to regulate their cortical activity using the feedback information as a guide. The 
plausibility of neurofeedback as a clinical tool has been investigated as far back as 1994 (Baehr, 
Rosenfeld, & Baehr, 2001) and research continues to this day (Peeters, Oehlen, Ronner, van Os, & 
Lousberg, 2014; Peeters, Ronner, et al., 2014; Quaedflieg et al., 2016). Although more research is 
needed, research indicates that the efficacy of neurofeedback may be similar to that of traditional 
methods (Cheon, Koo, & Choi, 2016; Peeters, Oehlen, et al., 2014). Neurofeedback is attractive 
because it could help overcome some of the attitudinal barriers to treatment, could be more convenient 
and cost-effective than traditional methods, and targets biological, evidence-based signals. 
 
 Attitudinal barriers 
The desire to deal with depression on one’s own and the perception of not needing help are 
two of the most significant attitudinal barriers to treatment (Andrade et al., 2014; Mohr et al., 2010).  
Neurofeedback could overcome these barriers due to the potential for self-administration. Unlike 
seeking help from mental health professionals, neurofeedback protocols only require an EEG headset 
for recording and a computer or laptop for providing feedback. Those who wish to deal with 
depression themselves could prefer neurofeedback to traditional treatment as it is a tool they can use to 
help themselves rather than a concession that they require external help.  Those who experience low 
perceived need of treatment might be less averse to neurofeedback because it doesn’t require engaging 
with mental health facilities to utilise. In both cases neurofeedback is less likely to be negatively 
affected by these barriers than other treatment methods are. With cheap headsets now available 
neurofeedback could be undertaken unsupervised at home. 
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 Cost and convenience 
 The structural issues of cost and convenience are also significant barriers to treatment. The 
cost of CBT is quite high with private appointments often costing over $100 per hour (Vos et al., 
2005). Other costs, such as transportation, time taken off work and prescriptions, further increase the 
financial strain. A self-administered neurofeedback protocol would require a one-off investment 
instead of an hourly rate. This could potentially save the individual significant costs, especially as 
many of the additional costs associated with traditional treatment would be avoided entirely. The 
equipment could also be loaned or hired if not needed on a regular basis.  
 
Targeting of Biological Signals 
 
 Alpha asymmetry 
 
Neurofeedback protocols for depression aim to alter the balance of alpha wave power in the 
frontal cortex (Peeters, Oehlen, et al., 2014; Peeters, Ronner, et al., 2014; Quaedflieg et al., 2016). 
Resting alpha waves have a property which distinguishes them from other frequencies. Alpha waves 
increase in amplitude when participants close their eyes and are attenuated when participants opened 
their eyes (Kirschfeld, 2005). This supports the idea that brain activity is responsive to external stimuli 
and that resting alpha activity is inversely related to brain activity. fMRI imaging of frontal regions 
shows that an increase in resting alpha wave activity correlates with a decrease in cortical activity 
(Laufs et al., 2003). Due to these findings, the alpha bandwidth has been the focus of a great deal of 
research.  
The study of mood and emotion is important to the understanding of many mental health 
disorders including depression. Early studies investigated the possibility of hemispheric asymmetry in 
the alpha band being a measure of trait-like affective response (Tomarken, Davidson, & Henriques, 
1990; Tomarken, Davidson, Wheeler, & Doss, 1992) with greater relative left activity predicting 
positive response and greater relative right activity predicting negative response. The measurement of 
asymmetric alpha power distribution is now referred to as alpha asymmetry. It is calculated by taking 
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the logarithmic power scores of an electrode pair and subtracting the left electrode from its 
homologous right electrode. The result is an index of the relative power difference between the pair 
with negative scores indicating higher left power and positive scores indicating higher right power.  
A more focused branch of research has assessed the relationship between alpha asymmetry 
and depression. Although state based variation occurs, there appears to be a large trait-like component 
to alpha asymmetry that relates to depression. About 40 – 50% of anterior alpha asymmetry appears to 
stem from a latent trait, while the rest is due to state based differences (Hagemann, Hewig, Seifert, 
Naumann, & Bartussek, 2005; Hagemann, Naumann, Thayer, & Bartussek, 2002). Alpha asymmetry 
shows test-retest reliability in healthy and depressed groups across time spans of weeks (Allen, Urry, 
Hitt, & Coan, 2004; Tomarken et al., 1992) and years (Vuga et al., 2006). It is predictive of depression 
in longitudinal studies of adolescents (Mitchell & Possel, 2012; Possel, Lo, Fritz, & Seemann, 2008). 
Lifetime MDD status correlates with alpha asymmetry regardless of current symptom severity 
(Stewart, Bismark, Towers, Coan, & Allen, 2010). Similarly, individuals with childhood onset 
depression show altered alpha asymmetry compared to controls even when symptoms are low (Miller 
et al., 2002). Children descending from families with a history of depression also exhibit increased 
alpha asymmetry (Bruder et al., 2012). All this evidence points towards the correlation between alpha 
asymmetry and depression being dependent upon stable trait features of both.  
The study of alpha asymmetry has also extended to anxiety. The rate of comorbidity between 
depression and anxiety disorder is extremely high (Approximately 60%; Kessler et al., 2003). With 
such a common relationship in place anything that correlates with one is almost certain to correlate 
with the other. Unsurprisingly, anxiety and alpha asymmetry appear to be correlated (Avram, Baltes, 
Miclea, & Miu, 2010; Bruder et al., 1997; Demerdzieva & Pop-Jordanova, 2011; Manna et al., 2010). 
As in depression, alpha asymmetry may also predict future anxiety scores (Blackhart, Minnix, & 
Kline, 2006). Thus, we have a picture in which two highly comorbid mood disorders are correlated 
with alpha asymmetry that demonstrates trait-like features.   
 Unfortunately, inconsistent results are commonplace in alpha asymmetry literature. This issue 
has been commented on in several reviews (Allen & Reznik, 2015; Olbrich, van Dinteren, & Arns, 
2015; Thibodeau, Jorgensen, & Kim, 2006). Some studies find positive results (Arns et al., 2016; 
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Bruder et al., 1997; Diego, Field, & Hernandez-Reif, 2001) while others find small, or no significant 
results (Blackhart et al., 2006; Gold, Fachner, & Erkkila, 2013; Segrave et al., 2011). This 
inconsistency of findings makes the interpretation of results difficult. The main problem is the variety 
of methodologies applied. While the alpha band used is typically between 7 – 14Hz, there is 
considerably variability between studies. For example, bands used include: 7.5 – 11.5hz(Lopez-Duran, 
Nusslock, George, & Kovacs, 2012), 7.5 – 12.5Hz(Miller et al., 2002), 8 – 12Hz(Gold et al., 2013) 
and 8 – 13Hz (Debener et al., 2000). There are also methods to calculate individualised alpha bands 
such as individual alpha frequency (IAF; Doppelmayr, Klimesch, Pachinger, & Ripper, 1998) and 
peak alpha frequency (PAF; Angelakis, Lubar, Stathopoulou, & Kounios, 2004). With such variability 
in methodology, corresponding variability in results is to be expected.  
 Of interest to this thesis are the differences between fixed and individualised alpha bands. The 
use of the same fixed alpha bandwidth for each participant has been argued against. There are 
significant inter-individual differences in expressed alpha frequencies (Bazanova, 2012; Doppelmayr 
et al., 1998; Haegens, Cousijn, Wallis, Harrison, & Nobre, 2014; Smit, Wright, Hansell, Geffen, & 
Martin, 2006). The presence of these differences at the individual level suggests that the use of fixed 
bands may not capture the desired signals in some participants and may include unwanted information 
in others. Klimesch (1999) described a method for calculating individualised alpha frequency (IAF) 
bands based on the alpha peaks centre of mass. This has seldom been applied in studies analysing AA 
and depression and with mixed results. One study finding no significance (Segrave et al., 2011) and 
another finding significance specifically in females (Tement, Pahor, & Jausovec, 2016).  
 The choice of electrode sites used for calculating AA is another major focus of this thesis. The 
electrode sites investigated vary between studies. Meta-analysis of depression- and anxiety-specific 
research found that F4/F3 was the only electrode pair to reach significance in depression (Thibodeau 
et al., 2006). However, this finding may reflect the absence of studies looking at many of the sites 
individually as many studies average power across left and right hemispheres. For example: Fp2/1 had 
nonsignificant results, but this conclusion was drawn from a single study. Subsequent studies that have 
used multiple electrode sites have found differing results with some null results for depression and 
anxiety (Segrave et al., 2011) and others showing positive (Demerdzieva & Pop-Jordanova, 2015). 
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The parietal regions are often neglected in favour of frontal sites despite there being significant 
findings in parietal sites (Stewart, Towers, Coan, & Allen, 2011). Detailed investigation of the roles 
played by other electrode pairs in both frontal and parietal regions is needed to improve our 
understanding of the relationships between AA and depression.   
  
 Fractal dimension 
 
AA is not the only measure that can be used for neurofeedback. The focus on AA began in the 
early 1990’s (Allen, Iacono, Depue, & Arbisi, 1993). Since then technological developments have 
resulted in vast improvements in computing power. This allows for timely usage of increasingly 
complex signal analysis techniques. During the 2000’s the use of nonlinear dynamical methods began 
to be used widely in EEG analysis (Stam, 2005). Recently, research has shown that these nonlinear 
measures may be useful in differentiating depressed from non-depressed individuals (Ahmadlou, 
Adeli, & Adeli, 2012; Akar, Kara, Agambayev, & Bilgic, 2015; Bachmann, Lass, Suhhova, & 
Hinrikus, 2013; Hosseinifard, Moradi, & Rostami, 2013).  
Fractal dimension is a nonlinear measure, which has been applied to neurofeedback (Wang, 
Sourina, & Nguyen, 2010) and also to depression (Ahmadlou et al., 2012). The purpose of fractal 
dimensions is best understood when the limitations of topological dimensions are made obvious. 
Normally when the dimension of something is considered we refer to its topological dimension; a 1-
dimensional object is defined only by its length (a straight line) and a 2-dimensional object is defined 
by both length and width (a plane). A straight line can be plotted on a plane, stretching and twisting 
this straight line will result in it taking up more space on the plane than it did before. It is still a line 
though it has only length and not width so it still has a topological dimension of 1. You can stretch and 
twist the line until it takes up every point of space on the plane, thus the 1-dimensional line becomes a 
2-dimensional plane. Logically, at some point in this process of twisting and stretching, the line 
stopped being truly 1-dimensional, but wasn’t yet 2-dimensional either. However, topological 
dimension is always an integer (1, 2, 3 etc) so it cannot describe this change adequately.  
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Fractal dimension is one way of addressing this issue and has been described as a measure of 
the complexity or space-filling capacity of a pattern. A straight line will still have a fractal and 
topological dimension of 1, but as it is stretched and twisted to take up more space the fractal 
dimension will increase fractionally (i.e 1.1, 1.2, 1.3) until the line fills the plane. At which point, the 
fractal and topological dimensions will both be 2. EEG time series can be plotted as a line on a 2-
dimensional graph. As EEG complexity increases, the space filled by the line will also increase. These 
changes will be reflected by the fractal dimension of the time series. In this manner, fractal dimension 
can be used as an index of EEG complexity, the closer to 2 the fractal dimension of the EEG signal 
becomes, the more complex the signal is.  
Two commonly used methods for calculating the fractal dimension are Higuchi’s Fractal 
Dimension (HFD; Higuchi, 1988) and Katz’s Fractal Dimension (KFD; Katz, 1988). The HFD 
provides a highly accurate measure of the fractal dimension but greater sensitivity to noise, the KFD is 
less accurate but faster and more resilient to noise (Esteller, Vachtsevanos, Echauz, & Litt, 2001). 
Comparison of the methods showed that, in the analysis of EEG the KFD values are often not correct 
and are unduly influenced by both amplitude and frequency of the signal (Raghavendra & Narayana 
Dutt, 2009). So, Higuchi’s method of calculating the fractal dimension should generally be used when 
analysing EEG signals and KFD is not assessed in this thesis.  
 
The Present Research 
As reviewed above, depression a common mental health disorder affecting a large proportion 
of the global population. In addition to its negative psychological symptoms, depression confers 
increased rates of cardiovascular disease, neurodegenerative disease and metabolic syndrome. 
Treatments of depression are various, covering both psychological and pharmaceutical domains. 
Current treatment options are often not enough to ensure remission. Investigating methods of 
treatment that can compensate or mitigate barriers to current treatments is needed. Neurofeedback is a 
potential method for treating depression that may circumvent several attitudinal and structural barriers 
to traditional treatment options. Current neurofeedback protocols focusing on depression use AA as a 
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target for manipulation despite the literature providing inconsistent results on the links between AA 
and depression. This inconsistency may be the result of varying methodologies. 
The aim of this thesis is to identify the optimal AA measure to use for neurofeedback and 
compare this with HFD as a possible distinct alternative. Several methodological variables will be 
assessed to determine the optimal way to calculate AA. These include: participant gender, eye 
condition, frequency bandwidth, and appropriate choice of electrode pair. Frontal AA (FAA) posterior 
AA (PAA), and HFD will be optimised separately as they are likely to involve distinct neural sources. 
The optimised measures will be placed into a stepwise linear regression model together. The results of 
the stepwise regression will give insight into the significance of the measures and whether they are 
additive. Part correlations will give further insight into the relationships between measures and the 
unique contributions of each. In all cases the criterion will be the proportion of The Personality 
Inventory for the DMS-5 (PID-5) depressivity scale that the measures account for. The assumption is 
that at least some of the brain activity specific to depression is causal and that its inhibition by 




Prior studies investigating the relationship between depressive symptoms and alpha 
asymmetry have tended to compare clinical samples with healthy controls. As discussed previously, 
previous research points towards a stable trait-like relationship between asymmetry and depression. 
Instead of using a clinical depression scale we will use the PID-5 depressivity subscale. The PID-5 is 
designed to identify traits distributed within the whole population. This contrasts with clinical scales, 
which diagnose psychopathology in a specific group with all scores representing some degree of 
dysfunction. PID-5 depressivity is trait focused, designed to measure a single underlying source of 
population variation, and also correlates well with depressive and dysthymic symptoms (Klein, 
Bufferd, Ro, & Clark, 2014). Importantly, its high scores enter and traverse the clinical range. This 
generality, purity and range make it ideal for the present experiment since it allows recruitment that 
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does not explicitly involve a patient population, a single factor source of variation against which to 
correlate measures, and a capacity to extend to the clinical domain.    
 
Gender 
There are clear gender differences in EEG signals (Armitage & Hoffmann, 2001). These 
differences have been observed in the alpha band and within depression populations (Miller et al., 
2002). Gender specific differences have also been investigated specifically regarding alpha asymmetry 
and depression (Arns et al., 2016; Jaworska, Blier, Fusee, & Knott, 2012). With wider EEG literature 
and specific alpha asymmetry literature showing major differences between genders it seems 
reasonable to keep the data analysis of participants separated by gender a priori. Therefore, in this 
thesis participants were split based on gender for all levels of analysis to ensure the most accurate 
results were obtained.  
 
Eye condition  
Typically, AA experiments use alternating blocks of open and closed eye conditions. AA 
scores are then calculated across both eye conditions. The alpha rhythm is strongest when the eyes are 
closed, and attenuated when the eyes open. Logically there could be significant differences between 




The accuracy of the fixed alpha band (8 – 13Hz) has been questioned. Doppelmayr et al. 
(1998) argued that a variety of factors can alter the distribution of EEG sub-bands between individuals 
and that the calculation of individual specific bandwidths might be more accurate. The authors 
compared a variety of different measures and concluded that individually determined alpha bands 
(IAF) were more accurate than fixed bands for identifying event related activity. The IAF is 
determined by identifying the central alpha peak between 6 and 14Hz. The points at which the peak 
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begins to rise and cease to fall are then marked ƒ1 and ƒ2 respectively. The gravity frequency between 
these two points is then calculated as (Σ (power * frequency))/( Σ (power)). The resulting frequency is 
the central alpha frequency from which sub-bands can be defined.  This approach has been tested in 
depressed populations only once, with results showing a correlation between antidepressant use and 
greater right alpha power but no correlation between depression and alpha asymmetry. A comparison 
of fixed band alpha and IAF will be conducted to determine any differences between the two. The 
optimal bandwidth will then be used in analysing frontal and parietal alpha asymmetry. 
 
Frontal alpha asymmetry electrode pairs  
 Most research has focused solely on the midfrontal area (F4 – F3) with any other electrode 
pairs being averaged for hemispheric comparisons rather than used individually. Despite this focus, 
findings continue to be unreliable. Following the same specific routines that provide inconsistent 
results is unlikely to be of much benefit. Instead, a wider view will be applied in this thesis. The 
popularity of the midfrontal area has resulted in a lack of research exploring other electrode pairs. This 
thesis will investigate the merits of a wider variety of electrode pairs. In the frontal region Fp2 – Fp1, 
F4 – F3, F8 – F7 and a synthesised AF4 – AF3 channel will be analysed individually. The optimal 
FAA measure identified will be considered the best location for use during neurofeedback.  Note that 
the use of the synthesised AF4-AF3 pair was suggested to us by Prof. Dr. Gerhard Stemmler (personal 
communication) as likely to provide the most accurate AA values. 
Hypothesis 1: Alpha asymmetry at F4 – F3 will account for the greatest proportion of PID-5 
depressivity variance in the frontal region. Most research has targeted this area suggesting that it is the 
most applicable site.  
 
Parietal alpha asymmetry electrode pairs.  
PAA has been linked to depression and there are claims it has been neglected (Stewart et al., 
2011). PAA will be calculated for P8 – P7 and P4 – P3. The eye condition and bandwidth will be the 
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same as identified in the prior FAA analyses. If the optimal PAA measure improves the 
FAA:depressivity model when included it will suggest that PAA and FAA are tapping into different 
processes; alternatively if PAA does not contribute unique variance to the model it will suggest that 
both frontal and parietal AA assess the same mechanism.  
Hypothesis 2: The optimal PAA measure will contribute significant unique variance when 
included in the FAA model. The effect will still be seen when HFD is included in the same model.  
 
Higuchi’s fractal dimension  
HFD has previously been used in neurofeedback protocols (Wang et al., 2010) and has been 
correlated with depression (Akar et al., 2015; Bachmann et al., 2013). HFD also analyses the spatial 
content of the signal, which AA cannot. This opens the possibility for both AA and HFD to be 
synergistic if used together. In this thesis HFD will be calculated for each frontal and parietal channel 
using the eye condition identified for the AA measures. Bandwidth will necessarily differ from AA as 
the Fourier transform used to acquire a specific bandwidth would discard the spatial content that HFD 
analyses. Instead two different bandwidths will be assessed: the full channel spectrum and a wavelet 
decomposed signal which approximates the alpha band. There is not enough prior research to warrant 
an electrode-specific hypothesis, the hypothesis for HFD is a question of whether any variance 
identified is unique to HFD or if it is shared with AA.  
Hypothesis 3: HFD will contribute significant unique variance when paired with FAA, PAA 
and when FAA, PAA and HFD are all included in a single model.  
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CHAPTER 2: METHODS 
 
The details provided in the experimental portion of this methods section are based on previous 
descriptions provided by Shabah Shadli and Julia McIntosh (See McIntosh, 2015), who carried out the 
testing of the participants, with the result that portions of this text overlap their reports. All data 
segmentation and analysis was carried out by me.  
 
Participants 
Participants for the study were recruited from the general population using Student Job Search 
and consisted primarily of students from the University of Otago. A total of 68 participants completed 
the experiment, 2 were excluded from analysis due to excessive artefacts in their EEG data. This left 
66 participants (41 females and 25 males) for data analysis. The ages of participants were between 18 
and 37 years and averaged 21.44 (𝑆𝐷 = 3.544) years. Ethical approval for the experiment and 
recruitment was obtained from the University of Otago Ethics Committee (Approval number: 
H15/005). Participants were reimbursed at a rate of $15 per hour for their time and inconvenience 
spent participating in the experiment. Participants who had undergone medical and/or psychological 
treatment for any type of emotional disorder were excluded from the study. Although handedness was 
not an exclusion criterion all participants were right handed. Informed consent was obtained from all 
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Apparatus/Materials 
 
Presentation of stimuli  
PC computer monitors (Screen size: 360mm x 375mm) were used to present task stimuli and 
the questionnaire program. Participants were seated on an office chair in front of the computer desk 
with the monitor at eye level.    
 
Questionnaires & demographics 
Participants were presented with computer-delivered questionnaires. These questionnaires 
were identical to those used by McIntosh (2015). They were delivered in two parts: the first was 
presented prior to the EEG task; the second was delivered after completion of the EEG task. The first 
set of questionnaires contained the Spielberger State – Trait Anxiety Inventory Y-form (STAI; 
Spielberger, Gorusch, Lushene, Vagg, & Jacobs, 1983) Trait Anxiety items, the Eysenck Personality 
Questionnaire-Revised (EPQ-R; Eysenck & Eysenck, 1993) Extraversion and Neuroticism items and 
the Behavioural Activation System/Behavioural Inhibition Systems (BIS/BAS; Carver & White, 1994) 
BIS scale items. The second set contained the Anhedonia, Anxiousness, Depressivity, Emotional 
Lability, Intimacy Avoidance, Perseveration, Risk Taking, Restricted Affectivity, Separation 
Insecurity and Withdrawal scale items from the Personality Inventory of the DSM-5 (PID5; American 
Psychiatric Association, 2013). Questions about sleep and history of depression were also included. In 
addition to the various scales participants also provided demographic information about themselves. 
This included age, gender ethnicity and handedness. For the purposes of this study only the PID-5 
Depressivity scale was used to measure trait depressivity. The PID-5 has good reliability and validity 
(Krueger & Markon, 2014) and scores can encompass both clinical and community samples (Markon, 
Quilty, Bagby, & Krueger, 2013).  
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EEG recording 
 EEG data were recorded (by either Julia McIntosh or Shabah Shadli) using a 32-channel 
Waveguard EEG cap (ANTneuro, Netherlands). Three different sizes of cap were available to ensure 
that participants were fitted with adequately sized caps. These sizes were large (57-64cm), medium 
(53-57cm) and small (47-53cm). The electrodes on the cap were arranged in accordance with to the 10 
-20 electrode placement system.  EEG was recorded from 18 channels: Fp1, Fpz, Fp2, F7, F3, Fz, F4, 
F8, T7, C3, Cz, C4, T8, P7, P3, Pz, P4, and P8. The EEG used a linked ears reference recorded at A1 
and A2.  To improve scalp conductance and improve EEG recording clarity Electro-gel (Electro Cap 
International, USA) was injected into all electrodes using a 3ml syringe and a Precision Glide 16-
gauge blunt needle (Becton, Dickenson & Co, New Jersey, USA). Impedance between scalp and 
electrodes was measured using an ASA Neurotechnology EEG machine. Resting EEG data was 
recorded in 1 minute blocks of eyes open (EO) or eyes closed (EC). As power frequencies are known 
to differ between these conditions (Barry, Clarke, Johnstone, Magee, & Rushby, 2007) markers were 
placed in the data to differentiate conditions. Recording of data was conducted at a sampling rate of 
256Hz and raw EEG was filtered using a 1 – 36Hz bandpass filter. A total of 8 minutes of resting data 
was recorded with the eyes open (EO) and eyes closed (EC) blocks arranged as follow: EO, EC, EO, 
EC, EC, EO, EC, EO. All experiments took place in a certified body protected area for electrical 
recording in the Department of Psychology at the University of Otago.  
 
Procedure 
Upon their arrival participants were all given information sheets describing the experiment in 
detail (see Appendix A). Participants were given the opportunity to ask about anything that they 
wished regarding their participation.  Signed informed consent was obtained from those participants 
who desired to continue in to the experimental session (Appendix A).  
Prior to commencing any tasks, participants were fitted for an EEG cap. The experimenter 
first measured the circumference of the participants head to ensure the correct sized cap was used. A 
blue marker was then used to mark the locations of FP1 and FP2 according to the international 10:20 
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system. Participants were then seated at a computer where they completed the first part of the 
questionnaire program after being instructed to work continuously and not to dwell too long on any 
single question. This part of the experiment would typically take 10 – 15 minutes to complete.  
In the next stage of the experiment participants were moved into a certified body protected 
area for electrical recording. The participant was seated in front of another computer screen and the 
appropriate size EEG cap was fitted to them by the experimenter. Once fitted the cap was connected to 
the ASA Neurotechnology EEG machine which allowed the experimenter to view the impedance of 
each electrode. Electrode gel was injected into each electrode using a blunt needle. Gentle abrasion by 
the needle was used to move dead skin and hair, increasing the conductance between scalp and 
electrode. In this manner impedance was reduced to below 20KΩ for every electrode to ensure clear 
EEG recording. This process often took 20 – 40 minutes to complete.  
Two tests were then conducted by the experimenter to ensure that the EEG was recording 
properly. First participants were instructed to close their eyes and relax for a brief period of time to 
accentuate alpha rhythm. After this the experimenter asked participants to blink their eyes 
continuously for a few seconds. Through observation of the recording EEG during these tasks the 
experimenter determined whether the recording system was functioning correctly. In cases where it 
appeared that the recording was not functioning correctly the experimenter would return to adjusting 
the impedances. Once the experimenter was satisfied that the recording was functioning smoothly and 
accurately recording of resting EEG would begin. A visual display on the monitor told the participants 
when to close their eyes. The experimenter verbally informed the participant when they needed to 
open their eyes.  
Following the resting EEG task participants undertook a Stop-Signal Task. Data from the SST 
are not analysed or discussed in the current thesis. After the SST task the EEG cap was disconnected 
from the ASA Neurotechnology device and the cap was removed from the participants’ head by the 
experimenter. Markings made during the fitting process were wiped off using cleansing wipes and 
paper towels were provided for the participants to remove any electrode gel. Participants then returned 
to the computer to complete the second part of the questionnaire program (which included the 
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depressivity questions). Upon completion, the participants were given monetary reimbursement for 
their time and inconvenience of $15 per hour. 
 
Data Processing & Analysis 
 
 Note that, unlike the data collection, all data processing and analysis were carried out by me; 
as was development of the EEGLAB procedures and MATLAB code required for the analyses. 
 
Primary pre-processing  
EEG data and associated event markers were exported from ASA and imported to the 
EEGLAB toolbox for MATLAB. As the location and name of each channel did not carry over from 
ASA to EEGLAB, a separate EEGLAB-compatible file was created. This file listed names and polar 
coordinates matching the original EEG recording.  As this procedure had not been carried out in the 
laboratory before, I tested it using differing sine waves and by comparing ASA data with EEGLAB 
data to ensure it was accurate. As the EEG recording included both Stop Signal Task and resting EEG 
the event markers were used to select only data collected during the resting task. These data were then 
split into eyes open and eyes closed datasets for each participant. Each dataset was split into 1 second 
(256 sample) epochs with no overlap in preparation for artefact rejection, as EEGLAB requires data to 
be epoched for some artefact rejection methods. All this initial processing was automated using 
MATLAB scripts developed by me as part of this project.  
 
Artefact rejection  
The epoched data sets were visually inspected for gross artefacts. Identified epochs with 
artefact were removed from the dataset and boundary markers were inserted to mark their previous 
location. Independent component analysis (ICA) was applied to the remaining epoched data. ADJUST 
1.1 (Mognon, Jovicich, Bruzzone, & Buiatti, 2011) was used to analyse the ICA results and remove 
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artefact components to leave ‘clean’ EEG. The artefact-free datasets were then converted from 
epoched to continuous data and two synthesized channels were created. AF3 was approximated by 
averaging F3 and Fp1; AF4 was approximated by averaging F4 and Fp2. Note that these averages are 
of the raw waveforms and prior to Fourier transform. 
 
Figure 2.1. EEG processing pathway. As AA and HFD measures analyse details of data that are 
mutually exclusive the processing pathway splits after artefact and eye blink removal. IAF = 
Individual Alpha Frequency; Fixed = Fixed alpha bandwidth; HFD = Higuchi’s Fractal Dimension; 
MRA = Multiresolution Analysis. 
After artefact removal, the processing pathway splits. In this thesis, we are investigating both 
AA, which is a power measure localised in the frequency domain, and HFD, which is calculated from 
the signal localised in its time domain. Unfortunately, a signal cannot be localised in both time and 
frequency. This is because time and frequency domains are the inverse of each other; increased 
frequency resolution comes at the cost of reduced temporal resolution and vice versa. It is a 
fundamental limit imposed by the signal itself (Gabor, 1946).  
To gain accurate AA measurements we used the FFT to localise the EEG signal in the 
frequency domain. In the process, we lose the time domain information of the signal. We learn the 
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amplitude of the signal at specific frequencies, but have no idea when those frequencies occurred. For 
HFD we need to retain time domain information but we also want to investigate the fractal dimension 
of the alpha band. To achieve this, we used multiresolution analysis (MRA; Mallat, 1989) which 
allows us to strike a balance between temporal and frequency resolution which is explained in greater 
depth later in this chapter. HFD could then be calculated for both the MRA decomposed signal and the 
full bandwidth signal (referred to as full channel (FC) dataset). 
 
Power-frequency processing  
Alpha asymmetry analysis requires signal power to be localised by frequency. The FFT is 
used to localise the signal by frequency and the signal power is then calculated from the FFT output as 
amplitude squared. The relationship between FFT output and frequency resolution is: 
   𝑁 = 𝐹𝑠/𝑑𝐹       (1) 
   ∴ 𝑑𝐹 = 𝐹𝑠/𝑁       (2) 
Where N is the number of samples, Fs is the sampling rate and dF is the frequency increment 
(resolution). Our sampling rate was 256Hz, to obtain a frequency resolution of 0.5Hz our epochs 
needed to have 512 samples each. FFTs assume that the input waveform is one period in a periodic 
signal, which is problematic in the case of EEG signals as epochs are likely to contain truncated data. 
This results in spectral leakage and may skew the results of the FFT. To avoid this, we applied a 
Hanning window to the data which was defined as: 
    𝑤(𝑛) = (0.5 (1 − cos (2𝜋
𝑛
𝑁
))) , 0 ≤ 𝑛 ≤ 𝑁   (3) 
Where 𝑁 is the total number of samples and 𝑛 = 0, 1, 2, … , 𝑁. The window applies a 
weighting function to the epoch reducing the amplitude of the outside edges of the data and increasing 
the amplitude of the central points. Epochs were overlapped 25% at each end to account for the 
attenuating effect that windowing has on the outside edges of the epochs.  
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 Power extraction  
The FFT of each windowed epoch was calculated using MATLAB’s indigenous FFT function 
(GIVE NAME). As the FFT calculation involves summing across the number of data points the output 
is divided by the length of the input. Each bin of the normalised output represents one step of the 
frequency increment. The Nyquist frequency is half of the sampling rate; frequency bins above the 
Nyquist frequency are discarded due to aliasing.  
    𝑌(𝑘) = 𝑌 (1, 2, … , (
𝑁
2
))      (1) 
We then multiply the remaining data by two to account for the amplitudes discarded. When 
windowing the data, a weighting factor is applied across the epoch. To acquire the correct amplitudes 
this weighting factor must be accounted for. A scaling factor is calculated that reverses the weighting 
effecting and the epoch is multiplied by this factor.  
     𝐴 = (
2
𝑤𝑛𝑡
 ∙ 𝑌)       (1) 
     𝑝 = 𝐴2       (2) 
 
Where 𝐴 is amplitude, 𝑝 is power and the scaling factor (wnt) is calculated as: 
    𝑤𝑛𝑡 = 𝑚𝑒𝑎𝑛(𝑤(𝑛) ∙ 𝑤(𝑛))     (1) 
The resulting data consists of a series of frequency bins which contain absolute power values 
specific to that frequency, which were then converted to a natural logarithm to reduce the influence of 
scale differences and skewness resulting from the power transform. A third dataset for each participant 
was obtained by averaging together open and closed power values to create combined condition power 
scores. Logarithmic power scores were then averaged across all epochs of each dataset to give us an 
index of average absolute power. Both the FFT and power extraction processes were run using 
MATLAB scripts that I wrote. They were tested using time series constructed from sine waves to 
ensure that each step produced the correct results. 
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Fixed alpha frequency bands 
For the fixed band alpha asymmetry measure an alpha band of 6 – 12Hz was used. This 
bandwidth is based on the “transition frequency” (Doppelmayr et al., 1998); the point at which alpha 
desynchronises from theta.  This bandwidth was split into 4 sub-bands: low 2 (6-8Hz), low 1 (8-
10Hz), high (10-12Hz) and total  (6-12Hz).  
Fixed alpha asymmetry. AA scores were calculated for each frontal (Fp2 - Fp1, Af4 - Af3, F4 
– F3, F8 – F7) and parietal (P4 – P3, P8 – P7) homologous electrode pair by subtracting the 
logarithmic average alpha power within each sub-band of left electrodes from right electrodes (ln 
(Right) – ln (Left) alpha power). AA scores were calculated for every sub-band in each pair, resulting 
in four AA scores in each homologous pair, e.g., for the homologous pair Fp2/Fp1 the following AA 
scores were calculated: Fp2 – Fp1low 2, Fp2 – Fp1low 1, Fp2 – Fp1high and Fp2 – Fp1total.  
 
Individual alpha frequency bands 
Proposed by Klimesch, Schimke, and Pfurtscheller (1993) IAF is a measure that can be used 
to calculate individual alpha bandwidths. To obtain IAF for each subject we first took the average 
power over all electrodes and plotted it over frequency. The frequency window is manually 
determined by visual inspection of the plotted data. Ƒ1 is the point at which the main alpha peak 
begins to ascend; ƒ2 marks the end of descent. We then calculate the gravity frequency between ƒ1 
and ƒ2 as follows: 




The resulting gravity frequency is the point within the alpha spectrum that marks the transition 
between high and low alpha bands. Across participants the mean IAF values were 9.91Hz and 9.9Hz 
for eyes closed and eyes open conditions, respectively.  The alpha band was split into low 2 (IAF-4Hz 
to IAF-2Hz), low 1 (IAF-2Hz to IAF) high (IAF to IAF+2) and total (IAF – 4Hz to IAF +2Hz).  
IAF alpha asymmetry. AA scores were calculated in the same manner as for the fixed bands 
except with average alpha power in each sub-band calculated according to the IAF sub-bands. 
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Multiresolution analysis  
Two measures of HFD were calculated: (1) the HFD of the time localised signal across the 
entire bandwidth of the channel and (2) the HFD of an approximate alpha bandwidth. The full channel 
HFD is calculated directly from the filtered and artefact free EEG signal. To obtain an approximate 
alpha bandwidth MRA is used.  
MRA applies complimentary lowpass and highpass filters to the signal. The filters are 
symmetrical around the central frequency of the signal. In this experiment, a Daubechies 4th order 
wavelet is used for the filtering, in the same manner as Adeli, Ghosh-Dastidar, and Dadmehr (2007).  
Applying these filters splits the signal in two, with the low frequency components contained in one 
signal and the high frequency components in the other. Each of these new signals now contain half the 
frequencies of the original, the signals are also down sampled by a factor of 2 to reflect their new 
frequency ranges. This process is repeated until the desired bandwidth is reached.  
 
Figure 2.2. Multilevel wavelet decomposition tree 
 
At each step of the decomposition the number of samples is halved. Therefore, it is crucial to 
ensure that the original signal has enough samples to allow an accurate HFD to be calculated from the 
output of the MRA. To obtain accurate fractal dimension scores Accardo, Affinito, Carrozzi, and 
Bouquet (1997) suggest that 𝑁 ≥ 125. The band approximating alpha (8-16Hz) requires 4 levels of 
wavelet decomposition to extract. To ensure that the extracted bandwidth contained 𝑁 ≥ 125 data 
points 25% overlapping epochs of 20 seconds each were used. At our sampling rate of 256Hz this 
gave each epoch a total of 5120 data points and leaving a total of 320 data points after 4 levels of 
halving.  
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 Higuchi’s fractal dimension  
Higuchi’s Fractal Dimension (Higuchi, 1988) is a method of calculating the Fractal 
Dimension (FD) of a time series. For EEG signals the HFD will return a value between 1 and 2 with 
higher values indicating increased complexity within the signal. A fractal is self-similar at all scales, 
large or small. The HFD creates multiple time series by subsampling the signal repeatedly. This 
creates the original signal at a variety of different scales.  
 The length of the curve for each new time series is then calculated and averaged across the 
sets. This is repeated for the different scales and plotted on a doubly logarithmic graph. The fractal 
dimension is the slope of this graph.  
 The HFD first generates new time series described as: 
 𝑋𝑘 
𝑚;  𝑋(𝑚), 𝑋(𝑚 + 𝑘), 𝑋(𝑚 + 2𝑘), … 𝑋 (𝑚 +  [
𝑁−𝑚
𝑘
]  × 𝑘)  (𝑚 = 1, 2, 3, … , 𝑘),   (1) 
Where X is the original time series, m indicates the initial time and k is the interval time. For each of 
the new time series 𝑋𝑘
𝑚 the length of the curve is calculated by: 











} 𝑘⁄    (2) 
While the length of the curve for 𝑘, 𝐿(𝑘) is the average value over 𝑘 sets of 𝐿𝑚(𝑘). If 𝐿(𝑘) is 
proportional to 𝑘−𝐷 then the curve has the fractal dimension 𝐷. 𝐷 is the slope of a least mean squares 
straight line applied to 𝐿(𝑘) and 𝑘 plotted on a doubly logarithmic graph.   
   log(𝐿(𝑘)) ~ log (
1
𝑘
)       (3) 
 
 
Statistical analysis          
 
 All statistical analysis was conducted using IBM SPSS Statistics package (version 24). One-
way, repeated measures ANOVAs were used to compare FAA eye condition, bandwidth, and HFD 
bandwidth. Signed proportion of variance (R2 value * 100, with the signed direction of correlation 
added) gives us the variance of PID-depressivity accounted for as a percentage, while including the 
Page - 31 
sign ensures that the direction of correlation is not ignored. Importantly, percent variance avoids the 
skew of raw correlation scores. These ANOVAs are comparing the mean proportional variance 
accounted for by each condition. The conditions that account for the greatest proportional variance 
will be used considered optimal, if differences are not apparent then the condition most commonly 
used in previous literature will be preferred. Optimal conditions for FAA were also applied to PAA. 
HFD used the same eye condition as FAA and PAA, but an optimised HFD bandwidth was obtained 
by comparing the proportional variance of FC and MRA conditions.  
 
 Frontal alpha asymmetry  
With the optimal conditions for eye and bandwidth defined, the sub-bands of homologous 
electrode pairs were regressed against PID-5 depressivity using linear regression. The strongest sub-
bands for each pair were identified from their R values. Regressions were run comparing the strongest 
sub-bands both within and between homologous pairs. Within pairs the previously identified sub-band 
was paired with each other sub-band (i.e., Fp2 – Fp1high paired with Fp2 – Fp1total, then with Fp2 – 
Fp1low 2 and so on) and a regression was run on each pair. The resulting part correlations were then 
analysed to determine if the strongest sub-band was representative of the total variance accounted for 
within the homologous pair. Between homologous pairs regressions compared the strongest sub-band 
from each homologous pairs (i. e., Fp2 – Fp1high paired with AF4 – AF3high). The part correlations 
from these regressions can be used to determine whether the variance accounted for by one 
homologous pair is representative of other homologous pairs. Note that the goal of these analyses is to 
demonstrate minimal differences between measures and so a significance test is not appropriate. If the 
variance accounted for by these paired measures is shared between them, then the strongest of the two 
can be said to be representative of the other. However, if there is a low proportion of variance 
accounted for by each and part correlations remain high, then one measure is not representative of the 
other as their contributions are unique.  
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Parietal alpha asymmetry  
The same analyses used for FAA were used for parietal alpha asymmetry (PAA).  
 
Higuchi’s fractal dimension  
There are no sub-bands for HFD and it is calculated at every electrode. To keep the HFD 
analysis like the AA analysis, the strongest HFD scores from homologous pairs were selected based on 
their R value. The part correlations were compared both within pairs and between pairs as was done in 
the AA analysis. The optimal measure (or combination thereof) was determined in the same manner as 
FAA and PAA.  
 
 Combined measures  
The additivity of PID-5 depressivity variance accounted for by FAA, PAA and HFD was 
analysed using stepwise linear regression. Stepwise regression identifies the strongest correlate, then 
checks for other variables that add additional significant variance to the model step by step. If the 
different measures all provide the same variance, then only the strongest will be included as the others 
won’t contribute extra variance to the model. However, if the variables all contribute significant 
unique variance the model will include them all. It is expected that all three variables will be included 
in the stepwise model. The extent of additivity (or lack thereof) will be further analysed through the 
part correlations of the variables pairwise and as a group.  
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CHAPTER 3: RESULTS 
 
This chapter provides the results of the data analysis, split into four separate sections. The first 
section deals with optimisation of frontal alpha asymmetry (FAA), which is the primary focus of this 
study. The second and third sections deal with optimisation of parietal alpha asymmetry (PAA) and 
Higuchi’s fractal dimension, respectively.  In each case the issue is to choose the optimal 
representative measure and test how far it captures the available variance. The fourth section then 
assesses how far these distinct types of representative measure make unique contributions to 
prediction of depressivity. 
As discussed at the end of chapter 1, the separation of gender was justified a priori and so 
separate analyses at every stage were conducted for male and female participants. Comparison of 
different eye and bandwidth conditions was conducted using the signed proportion of variance (%). 
This was obtained from R2 values, multiplied by 100 to give percentage of variance accounted for by 
the variable in question. Including the original sign of the correlation (+/-) ensures that the direction of 
correlation is not lost. Furthermore, signed proportion is inherently normalised – the values can only 
range between -100% and +100%. These comparisons were completed using one-way, repeated-
measures ANOVA. 
 Comparisons of eye (open/closed/combined) and bandwidth conditions calculated for FAA 
were also used in PAA. This ensures consistency between the various AA measures. HFD used the 
same eye condition as FAA but cannot use the same bandwidth as the AA measures because it is not a 
power spectrum measure. Instead, the HFD of full channel bandwidth and an approximated alpha band 
were compared. This ensured that eye condition and bandwidth remained consistent across all 
measures, reducing the number of conditions to the minimum necessary.  
The strongest predictor variables can be readily identified using their zero order correlations. 
That approach ignores the deeper structure of the data, potentially losing vital information. To ensure 
important relationships were not missed, the part correlations of all variables were investigated. This 
allowed us to identify what the unique contributions of each variable are and provide greater 
confidence that we are not missing anything when selecting a single representative measure.  
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Unless stated otherwise, all correlations discussed are between predictor variables (FAA, PAA 
and HFD) and PID-5 depressivity.  
 
Alpha Asymmetry – Eye Condition 
 
Introduction  
The difference in PID-5 correlation between open, closed and combined eye conditions were 
compared using a one-way, repeated-measures ANOVA.  The three conditions, in the order closed, 
combined, open were treated as successive levels for the purpose of linear and quadratic trend 
analysis. The means and standard deviations for each gender are displayed below in Table 3.1. 
Females displayed positive mean correlations in the combined and open eye conditions while males 
displayed negative correlations in those conditions. In both genders, the mean variance accounted for 
is higher in combined and open conditions than in the closed condition.  
Table 3.1 
Mean and standard deviation of signed proportion of variance by eye 




Closed Combined Open 
Female -0.61(.51)  2.88(4.88)  3.08(3.82) 32 
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Results 
 
Female. Sphericity was not violated (χ2 = 4.754, p = .093). There was an effect of eye 
condition on depressivity correlations (F(2, 62) = 18.940, p < .001, η2 = .379). The closed eye 
condition provided lower values than the open eye condition([linear] F(1,31) = 24.454, p < .001, η2 = 
.441).  Combined eye condition differed from the average of open and closed conditions 
([quadratic]F(1,31) = 10.294, p = .003, η2 = .249). Pairwise comparison showed that open and 
combined conditions were not reliably different from each other (p = .724), showing that the quadratic 
effect was fuelled by the difference between combined and closed eye conditions.  
 
Male. Mauchly’s Test of Sphericity indicated that sphericity had been violated (χ2 = 13.869, p 
= .001) and therefore degrees of freedom were taken as Greenhouse-Geisser estimates.  
There was an effect of eye condition on depressivity correlations (F(1.460, 45.250) = 4.373, p 
= .029, η2 = .124). The open eye condition appears to be stronger than the closed eye condition 
however, this trend was on the margin of significance ([linear]F(1,31) = 4.064, p = .053). The 
combined eye condition provided stronger correlations than the average of open and closed conditions 
([quadratic] F(1, 31) = 5.512, p < .025, η2 = .151). Pairwise comparisons showed that this effect was 
largely driven by the difference between combined and closed (p = .001) as no difference with the 
open eye condition existed (p = .947).  
 
Discussion  
In male and female participants, the combined eye condition provided stronger correlations 
than the average of open and closed conditions. This effect was largely driven by the closed condition 
which was consistently weaker than the combined condition. The open condition was not substantially 
different to the combined eye condition in either of the groups.  
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 These results indicate that either combined or open eye conditions could be preferred. The 
benefit of the combined eye condition is that it has been used extensively in the literature. The open 
eyes condition has not been targeted in the resting AA literature. Therefore, the combined eye 
condition was selected for the following analyses due to its prevalence in the literature and the lack of 
significant differences between combined and open eye conditions. 
 
Alpha Asymmetry - Frequency Band Type (Fixed versus IAF) 
 
Introduction 
To determine whether fixed or IAF frequency bands are best, a one-way repeated measures 
ANOVA was used. Given the results in the previous subsection, only combined eye variables were 
included, so the number of variables in each condition is halved from the previous analysis, which had 
fixed and IAF scores for each variable. Mean and standard deviation for each gender are displayed in 
Table 3.2. In both bands, females display positive mean values while males display negative values.  
Table 3.2 
Mean and standard deviation of signed proportion of variance by 





Female  3.071(1.269)  2.705(1.207) 16 










 Female. As can be seen in Table 3.2, female participants exhibited somewhat stronger average 
signed proportion of variance in the fixed band. This difference was not reliable (F(1,15) = .609, p = 
.447). 
 
 Male. The Fixed band in male participants showed somewhat stronger (negative) signed 
proportion of variance than IAF although the difference is not reliable (F(1,15) = .650, p = .433). 
 
 Discussion  
The fixed bandwidth tends to have higher signed proportion of variance than the IAF band. 
This is visible in both male and female participants, although the differences between Fixed and IAF 
are not reliable. The fixed band is easy to calculate, applies equally to all participants and has featured 
widely in research for many years. IAF may be a more accurate measurement of the alpha band but it 
must be calculated manually for each participant and, in our data, does not appear to provide an 
advantage in relation to depressivity. With higher values and simplified application, the fixed 
bandwidth was chosen as the better measure to be used in the other analyses of this thesis.  
 
Frontal Alpha Asymmetry – Electrodes and Sub-bands 
 
Introduction 
The analysis of alpha asymmetry used the combined eye condition and fixed frequency band 
as discussed in the previous sections. For each electrode pair (Fp1 – Fp2, Af4 – Af3, F4 – F3, F8 – F7) 
there were 4 sub-bands. These sub-bands were low 2 (6-8Hz), low 1 (8-10Hz), high (10 – 12Hz) and 
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total (6 – 12Hz).  There were thus 16 possible measures with which to predict depressivity from alpha 
asymmetry.  
 
 Results  
 Correlation matrices for each gender were calculated. Female correlations are displayed in 
Table 3.7, male correlations are displayed in Table 3.8. The frontopolar and anterior frontal electrode 
pairs displayed the strongest correlations. The best correlates for each electrode pair and gender are 
displayed in Table 3.3. Within-pair (i.e. between band) part correlations are displayed in Table 3.4 for 
females and Table 3.5 for males. Between-pair part correlations for males are displayed in Table 3.6, 
no between-pair comparisons were needed in female participants as only one pair was reliable.  
Table 3.3 
 
Best FAA measures of PID-5 depressivity in each homologous pair by gender.   
Channel Pair 
Females  Males 
Sub-band % p  Sub-band % p 
Fp2 - Fp1 High 16.1 .009 
 
High -21.8 .018 
Af4 - Af3 Total 4.8 .171 
 
High -29.7 .005 
F4 - F3 High -1.1 .507 
 
High -4.0 .336 
F8 - F7 Total 2.5 .326 
 
Total -21.3 .020 
Note: All values are correlations represented as signed percentage of variance. 
 
  
Female. The high and total sub-bands provided the accounted for the most proportional 
variance in every electrode pair. The overall best correlate was found at Fp2 – Fp1high (F(1,39) = 
7.487, p = .009, R = .401). No other pair contained any reliable correlations.  
As can be seen in Table 3.4, Fp2 – Fp1high displays a higher part correlation than any other 
sub-band in females. The low 2 and low 1 sub-bands account for a negligible proportion of variance 
(1.1% and 1.3% respectively). There may have been a suppression effect between low 2 and high sub-
bands, identifiable by the sum of part correlations being greater than the proportional variance of the 
model (18.3% vs. 17.3%) but the effect is very small. The total band shared most of its variance with 
the high sub-band (11.5%). This effect is likely due to the total band encompassing the high sub-band 
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frequencies in its bandwidth, ensuring that they share some variance. The unique contribution of the 
total band is still low, only increasing the model’s value by 3.3% which is not enough to justify 
including it with the high sub-band measure.   
 
Male. The high sub-band accounted for the most proportional variance and was reliable at FP, 
AF and the lateral frontal electrode pairs (see Table 3.5). As can be seen in Table 5, the best correlates 
in each electrode pair were negative in direction. However, Fp2 – Fp1high is the only variable that is 
reliable in both genders, albeit with an inverted sign.  
Part correlations within homologous pairs can be seen in Table 3.5. Fp2 – Fp1high and Af4 – 
Af3high displayed far higher part correlations than any other sub-band. Suppression effects were seen 
between high and low 1 sub-bands at Fp2 – Fp1high, again visible as a higher combined unique 
variance than the model itself accounts for. F8 – F7total showed much higher values of shared variance 
than the other electrode pairs, this is likely due to the other being specifically high sub-band measures 
while the total band includes all 3 sub-bands.  
Part correlations between the reliable homologous pairs can be seen in Table 3.6. A large 
component of variance is shared between the predictors (24.7%). When paired with Af4 – Af3high, no 










PID-5 depressivity variance accounted for by the best frontal alpha asymmetry 





Variances  Modelc 
Zero-
order Part  Unique
a Sharedb  
Fp2 - Fp1        
High 16.1 4.6      
Total 14.8 3.3  7.8 11.5  19.4 
High 16.1 17.1      
Low 2 0.1 1.1  18.3 -1.0  17.3 
High  16.1 14.8      
Low 1 3.6 2.3  17.0 1.3  18.4 
Note. All values are correlations represented as signed percentage of variance. 
a Calculated as the sum of part correlations. 
b The difference between the sum of part correlations and the proportion of the 
model is the variance shared between variables. 
c The R2 of the model, converted to proportion of variance. 




PID-5 depressivity variance accounted for by the best alpha asymmetry measures 
and each other sub-band within their electrode pair for male participants. 
Band 
Correlations  Combined Variances  Modelc 
Zero-order Part  Unique
a Sharedb  
Fp2 - Fp1        
High -21.8 -19.4      
Total -4.7 2.3  21.7 2.4  -24.1 
High -21.8 -21.3      
Low 2 -1.4 0.8  22.1 0.6  -22.7 
High  -21.8 -24.5      
Low 1 -0.7 3.4  27.9 -2.7  -25.2 
Af4 - Af3        
High -29.7 -22.3      
Total -8.0 0.6  22.8 7.5  -30.3 
High -29.7 -29.6      
Low 2 -0.9 0.8  30.4 0.1  -30.5 
High  -29.7 -28.7      
Low 1 -1.1 0.1  28.9 1.0  -29.8 
F8 - F7        
Total -21.3 -7.2     
 
High -14.6 -0.5  7.8 14.1  -21.9 
Total -21.3 -13.0      
Low2 -8.4 0.1  13.1 8.3  -21.4 
Total -21.3 -12.1      
Low 1 -9.4 0.2  12.3 9.2  -21.5 
Note. All values are correlations represented as signed percentage of variance. 
a Calculated as the sum of part correlations. 
b The difference between the sum of part correlations and the proportion of the 
model is the variance shared between variables. 
c The R2 of the model, converted to proportion of variance. 
Page - 42 
Table 3.6 
PID-5 depressivity variance accounted for by the best alpha asymmetry 




Variances  Modelc 
Zero-
order Part  Unique
a Sharedb  
Paired       
 
Af4 - Af3high -29.7 -8.9      
Fp2 - Fp1high -21.8 -1.0  -9.9 -20.8  -30.8 
Af4 - Af3high -29.7 -10.9      
F8 - F7total -21.3 -2.5  -13.4 -18.8  -32.2 
Fp2 - Fp1high -21.8 -5.4      
F8 - F7total -21.3 -4.9  -10.3 -16.4  -26.8 
Combined        
Af4 - Af3high -29.7 -5.8      
Fp2 - Fp1high -21.8 -0.3      
F8 - F7total -21.3 -1.8  -7.9 -24.7  -32.5 
Note. All values are correlations represented as signed percentage of 
variance. 
a Calculated as the sum of part correlations. 
b The difference between the sum of part correlations and the proportion 
of the model is the variance shared between variables. 
c The R2 of the model, converted to proportion of variance. 
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Discussion 
The overall results show that the electrode pairs that best correlate with PID-5 depressivity 
differ between genders. Fp2 – Fp1high was the best correlate for females, Af4 – Af3high was the best 
correlate in males. Fp2 – Fp1high was also significant in males, making it the only common correlate 
between genders. Part correlations also show that Af4 – Af3high is a stronger predictor than Fp2 – 
Fp1high as it accounts for almost all the latter’s variance and contributes extra on top.  
 The aim of this experiment is to identify the optimal electrode pair for neurofeedback 
protocols. Even though Af4 – Af3high in males is the strongest, it is also a synthetic channel and we 
cannot be sure that an effect of similar strength would be obtained from real channels. Though not 
quite as strong, Fp2 – Fp1high comes from recorded data which allows us more certainty. The 
correlation at Fp2 – Fp1high is also the only finding to occur in both genders, albeit with opposite signs. 
These factors taken together indicate that the finding at Fp2 – Fp1 is robust. For these reasons Fp2 – 
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Table 3.7          




Af4 - Af3  F4 - F3 
High Low 1  Low 2  Total  High 
1 Depressivity  -         
2 Af4 - Af3: High  .15  -        
3 Af4 - Af3: Low1  .13  .39**  -       
4 Af4 - Af3: Low2  .11 -.24 -.07   -     
5 Af4 - Af3: Total  .22  .67***  .76***   .34*   -   
6 F4 - F3: High -.11  .75***  .20  -.14   .48***   - 
7 F4 - F3: Low1 -.06  .34*  .82***  -.07   .63***   .35* 
8 F4 - F3: Low2  .05 -.13  .04   .87***   .40**  -.10 
9 F4 - F3: Total -.06  .52***  .54***   .32*   .77***   .67*** 
10 F8 - F7: High  .14  .17 -.06  -.12   .00   .23 
11 F8 - F7: Low1  .13  .03  .50***   .09   .35   .02 
12 F8 - F7: Low2  .05 -.26 -.22   .56***   .02  -.14 
13 F8 - F7: Total  .16 -.02  .11   .25   .18   .06 
14 Fp2 - Fp1: High  .40**  .29*  .05  -.04   .18  -.03 
15 Fp2 - Fp1: Low1  .19  .18  .72***   .11   .57***   .00 
16 Fp2 - Fp1: Low2  .04 -.04 -.20   .68***   .21   .05 
17 Fp2 - Fp1: Total  .38**  .27*  .37**   .38**   .56***   .01 
 
Variable Depressivity 
F4 - F3  F8 - F7 
Low 1 Low 2  Total  High  Low 1 
1 Depressivity  -         
7 F4 - F3: Low1 -.06  -        
8 F4 - F3: Low2  .05  .14  -       
9 F4 - F3: Total -.06  .77***  .51***   -     
10 F8 - F7: High  .14 -.02 -.17   .02   -   
11 F8 - F7: Low1  .13  .22  .00   .12   .29*   - 
12 F8 - F7: Low2  .05 -.34*    .45**  -.03   .00   .27 
13 F8 - F7: Total  .16 -.07  .12   .06   .66***   .76*** 
14 Fp2 - Fp1: High  .40** -.09 -.03  -.08   .06  -.14 
15 Fp2 - Fp1: Low1  .19  .41**  .05   .23  -.15   .51*** 
16 Fp2 - Fp1: Low2  .04 -.20  .60***   .22  -.11   .06 
17 Fp2 - Fp1: Total  .38**  .09 .31*   .20  -.11   .25 
 Variable Depressivity 
F8 - F7  Fp2 - Fp1 
Low 2 Total  High  Low 1  Low 2 
1 Depressivity  -         
12 F8 - F7: Low2  .05  -        
13 F8 - F7: Total  .16  .61***  -       
14 Fp2 - Fp1: High  .40**  .01 -.03   -     
15 Fp2 - Fp1: Low1  .19 -.01  .17   .10   -   
16 Fp2 - Fp1: Low2  .04  .36*  .14  -.17   .03   - 
17 Fp2 - Fp1: Total  .38**  .18  .15   .60***   .69***   .41** 
* p < .05, ** p < .01, *** p < .001         
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Table 3.8 




Af4 - Af3  F4 - F3 
High Low 1  Low 2  Total  High 
1 Depressivity  -         
2 Af4 - Af3: High -.55**  - 
       
3 Af4 - Af3: Low1 -.11 .25  -  
     
4 Af4 - Af3: Low2 -.09 .32 .47* 
 
 -  
   




 -  
 






















































































F4 - F3  F8 - F7 
Low 1 Low 2  Total  High  Low 1 
1 Depressivity  -         
7 F4 - F3: Low1  .00  - 
       
8 F4 - F3: Low2  .02 .42*  -  
     
9 F4 - F3: Total -.07 .80*** .77*** 
 
 -    
 




 -  
 

















































 Variable Depressivity 
F8 - F7  Fp2 - Fp1 
Low 2 Total  High  Low 1  Low 2 
1 Depressivity  -         
12 F8 - F7: Low2 -.29  - 
       
13 F8 - F7: Total -.46* .67***  -  
     
14 Fp2 - Fp1: High -.47** .36 .61** 
 
 -  
   




 -  
 














* p < .05, ** p < .01, *** p < .001 
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Parietal Alpha Asymmetry – Bands and Electrodes 
  
 Introduction  
 The Combined eye condition and fixed bandwidth used for FAA was also used for PAA. This 
keeps the measures as consistent as possible. PAA scores were calculated for parietal electrode 
channels P8 – P7 and P4 – P3 in the low 2, low 1, high and total sub-bands. Part correlations are 
displayed in Table 3.9. Correlation matrices for female participants are presented in Table 3.10, males 
in Table 3.11.  
Table 3.9 
PID-5 depressivity variance accounted for by the best parietal alpha 
asymmetry measures and each other sub-band within their electrode pair for 
female participants. 
Band 
Correlations  Combined Variances  
Modelc 
Zero-order Part  Unique
a Sharedb  
P8 - P7        
Low 1 -13.8 -6.9      
Total -7.0 0.0  6.9 6.9  -13.9 
Low 1 -13.8 
-
11.6      
High -2.3 0.0  11.6 2.2  -13.9 
Low 1 -13.8 
-
13.6      
Low 2 -0.4 0.2  13.8 0.2  -14.0 
Note. All values are correlations represented as signed percentage of variance. 
a Calculated as the sum of part correlations. 
b The difference between the sum of part correlations and the proportion of the 
model is the variance shared between variables. 
c The R2 of the model, converted to proportion of variance. 
 
  








P4 - P3 P8 - P7 
High Low 1 Low 2 Total High Low 1 Low 2 
1 Depressivity  -        
2 P4 - P3: High -.05  -       
3 P4 - P3: Low 1 -.22  .22  -      
4 P4 - P3: Low 2  .01 -.02  .23  -     
5 P4 - P3: Total -.13  .66***  .75***  .54***  -    
6 P8 - P7: High -.15  .56*** -.03 -.02  .29*  -   
7 P8 - P7: Low 1 -.37**  .15  .39**  .28*  .41**  .36*  -  
8 P8 - P7: Low 2 -.06 -.09  .06  .54***  .22  .02  .29*  - 
9 P8 - P7: Total -.26  .33*  .17  .37**  .43**  .71***  .74***  .62*** 





Zero order correlations between parietal alpha asymmetry fixed sub-bands and depressivity in male participants.  
Variables Depressivity 
P4 - P3 P8 - P7 
High Low 1 Low 2 Total High Low 1 Low 2 
1 
PID-5 
Depressivity -        
2 P4 - P3: High -.13 - 
3 P4 - P3: Low 1  .03 .39* - 
     
4 P4 - P3: Low 2 -.02 .44* .53** - 
    
5 P4 - P3: Total -.05 .74*** .80*** .85*** - 
   
6 P8 - P7: High -.09 .41* .24 .07 .28 - 
  
7 P8 - P7: Low 1  .06 .36* .53** .11 .40*  .40* - 
 
8 P8 - P7: Low 2  .17 .36* .15 .62*** .49** -.04 .29 - 
9 P8 - P7: Total  .07 .55** .43* .40* .57**  .66*** .80*** .62*** 
* p < .05, ** p < .01, *** p < .001 




Female. Almost all correlations were negative in direction, the sole measure that was positive 
accounted for less than .01% of depressivity variance (see Table 3.10). In both parietal pairs the low 1 
sub-band accounted for the most variance with the total band trailing behind. Only the finding in the 
lateral pair was reliable. P8 – P7low 1 accounted for the most variance of all variables, with none of the 
other variables showing a part correlation greater than 1% (see Table 3.9). 
 
 Male. Males did not follow the same pattern as their female counterparts. The strongest 
correlate was P8 – P7low 2 which was positive, but only accounted for 2.9% of depressivity’s variance. 
The high sub-band in both pairs provided the next best measures, which were both negative and 
accounted for less than 2% of variance.  
 
 Discussion 
 In female participants P8 – P7low 1 accounted for the most proportional variance. Part 
correlations showed P8 – P7low 1 accounted for all useful variance in other bands. Therefore, P8 – P7low 
1 was chosen as the optimal PAA measure for females. P8 – P7low 2 accounted for the most proportional 
variance in male participants, however this finding was not reliable.  
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Higuchi Fractal Dimension – Bandwidth 
   
 Introduction  
The combined eye condition was used for HFD. However, as discussed in Chapter 2 HFD 
analyses the spatial content of the signal, which is lost in the FFT used to select the fixed bandwidth. 
Instead two different sets of bandwidths were compared. An MRA dataset obtained via a 4-level 
multiresolution analysis containing an approximate alpha band (8 – 16Hz) and the artefact-free full 
channel data containing the full bandwidth of the raw data. Signed proportional variance between 
HFD and PID-5 depressivity were calculated for each channel and bandwidth. The bandwidths were 
then compared using a one-way, repeated-measures ANOVA. The means and standard deviations of 
each are displayed in Table 3.12.  
 
Table 3.12 
Mean and standard deviation of HFD signed proportion 




MRA Full Channel 
Female 11.330(.833) 15.576(.891) 12 




Female. The full channel bandwidth accounted for a higher proportion of variance than the 
MRA bandwidth. This difference was reliable (F(1,11) = 9.380, p = .011, η2 = .460).  
 
Male. The full channel bandwidth accounted for a higher proportion of variance than the 
MRA bandwidth. This difference was also reliable (F(1,11) = 5.117, p = .045, η2 = .317). However, 
proportion of variance was low, less than 2% in both bandwidths.   
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Discussion 
In both male and female participants, the full channel bandwidth reliably accounted for more 
variance than the MRA HFD. Due to these findings, the full channel HFD was identified as the best 
HFD measure to analyse.  
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Higuchi Fractal Dimension – Electrodes 
 
 Introduction  
The HFD of each channel in the FC bandwidth was calculated. The correlation matrix for 
female and male participants can be seen in Table 3.15 and 3.16 respectively. To keep the method like 
those used in our AA analyses, the strongest correlate in each homologous electrode pairs was selected 
to move forwards. These correlates are displayed in Table 3.13. Partial and part correlations are 
displayed in Table 3.14. 
Table 3.13 
 
Proportion of PID-5 depressivity accounted for by best HFD measure at each 
homologous pair. 
Channel Pair 








Fp2 - Fp1 Fp1 13.2 .020 
 
Fp1 1.3 .588 
Af4 - Af3 Af3 16.4 .009 
 
Af3 0.7 .688 
F4 - F3 F4 18.5 .005 
 
F4 1.4 .574 
F8 - F7 F8 17.6 .006 
 
F8 3.6 .364 
P4 - P3 P3 19.4 .004 
 
P3 5.4 .264 
P8 - P7 P7 19.4 .004 
 
P8 2.5 .454 
Note: All values are correlations represented as percentage of variance, there were 






Female. HFD correlated with depressivity reliably in every channel (see Table 3.15). The 
level of intercorrelation was high across all channels. Parietal channels accounted for the most 
variance, with the lateral and medial frontal channels close behind (see Table 3.13). P7 displayed 
higher part correlations than all other identified correlates. When paired with P7 no other variable’s 
part correlation accounted for more than 2% variance (see Table 3.14).  
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Male. HFD was not reliably correlated with depressivity in any channel. Intercorrelation 
between the HFD’s of every channel was apparent (see Table 3.16), mimicking the intercorrelation 
observed in female participants. Frontopolar and anterior frontal channels accounted for less variance 
than other frontal and parietal channels (Table 3.13).  
Table 3.14 
       
Proportion of PID-5 depressivity accounted for by the best HFD measure paired with best HFD at 
each homologous pair in females. 
Channels 
Correlations Combined Variances 
Zero-order Partial Part Unique Shared Total 
P7 19.57 1.51 1.21    
P3 19.56 1.49 1.20 2.4 18.4 20.8 
P7 19.57 2.72 2.22    
F8 18.13 .97 .78 3.0 17.3 20.4 
P7 19.57 3.68 3.00    
F4 18.51 2.41 1.93 4.9 16.6 21.5 
P7 19.57 7.69 6.67    
Fp1 13.18 .35 .28 7.0 12.9 19.8 
P7 19.57 4.81 4.02    
Af3 16.39 1.05 .84 4.9 15.5 20.4 
Note: All values are correlations represented as percentage of variance, there were no negative 




In females HFD was significant at every electrode, with the parietal channels accounting for 
the most proportional variance. There was a very high level of intercorrelation between all variables 
and a similar R value with most variables sitting at around .40. This level of intercorrelation suggests 
that the choice of electrode is somewhat arbitrary as differences are small. In this experiment, P3 and 
P7 had virtually identical correlations. P7 was identified by stepwise regression as the better of the 
two, due to a very small difference in p-value so P7 was chosen as the best predictor. There were no 
significant HFD variables in male participants, showing a stark contrast between genders.  
  




Zero order correlations between full channel fractal dimension and PID-5 depressivity in female 
participants. 
  Variables Depressivity Af3 Af4 F3 F4 F7 F8 
1 Depressivity  -       
2 Af3 .40**  -      
3 Af4 .40* .94***  -     
4 F3 .36* .97*** .90***  -    
5 F4 .43** .96*** .96*** .95***  -   
6 F7 .31* .87*** .87*** .87*** .85***  -  
7 F8 .43** .89*** .92*** .88*** .91*** .96***  - 
8 Fp1 .36* .95*** .91*** .93*** .92*** .85*** .87*** 
9 Fp2 .35* .80*** .92*** .77*** .84*** .78*** .83*** 
10 P3 .44** .88*** .85*** .87*** .85*** .87*** .88*** 
11 P4 .39* .84*** .83*** .81*** .82*** .84*** .84*** 
12 P7 .44** .79*** .81*** .75*** .77*** .85*** .86*** 
13 P8 .40** .73*** .72*** .68*** .68*** .81*** .79*** 
  Variables Depressivity Fp1 Fp2 P3 P4 P7 P8 
1 Depressivity  -       
8 Fp1 .36*  -      
9 Fp2 .35* .84***  -     
10 P3 .44** .78*** .70***  -    
11 P4 .39* .75*** .67*** .97***  -   
12 P7 .44** .74*** .78*** .88*** .87***  -  
13 P8 .40** .66*** .61*** .85*** .90*** .89*** - 




























Zero order correlations between full channel fractal dimension and PID-5 depressivity in male 
participants. 
  Variables Depressivity Af3 Af4 F3 F4 F7 F8 
1 Depressivity  -       
2 Af3 .08  -      
3 Af4 .07 .95***  -     
4 F3 .10 .99*** .95***  -    
5 F4 .12 .96*** .98*** .96***  -   
6 F7 .10 .93*** .94*** .94*** .94***  -  
7 F8 .19 .91*** .93*** .92*** .94*** .94***  - 
8 Fp1 .11 .96*** .92*** .93*** .95*** .90*** .87*** 
9 Fp2 .03 .81*** .94*** .81*** .90*** .84*** .82*** 
10 P3 .23 .79*** .77*** .80*** .80*** .85*** .85*** 
11 P4 .20 .78*** .78*** .78*** .80*** .84*** .84*** 
12 P7 .01 .48** .44* .49** .46* .60** .52** 
13 P8 .16 .73*** .76*** .71*** .78*** .82*** .82*** 
  Variables Depressivity Fp1 Fp2 P3 P4 P7 P8 
1 Depressivity  -       
8 Fp1 .11  -      
9 Fp2 .03 .84***  -     
10 P3 .23 .74*** .64***  -    
11 P4 .20 .73*** .67*** .97***  -   
12 P7 .01 .46* .38* .56** .58**  -  
13 P8 .16 .75*** .72*** .81*** .86*** .65*** - 
* p < .05, ** p < .01, *** p < .001 
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Effect of Combining Measures. 
 
 Introduction  
 FAA is the primary measure of interest in this study. PAA and HFD were identified as 
measures that may supplement or replace FAA. PAA is calculated from a completely different region 
from FAA. HFD analyses a different aspect of the signal altogether. If both PAA and HFD are 
measuring different mechanisms to FAA, then they should contribute a large amount of unique 
variance to the FAA - depressivity model. To test this, the best FAA, PAA and HFD measures were 
each included in a stepwise linear regression. Zero order and part correlations are displayed in Table 
3.17.  
Table 3.17        
Proportion of PID-5 depressivity accounted for by the best FAA, PAA 
and HFD measures when paired and combined in female participants. 
Band 
Correlations  Combined Variances  
Modelc Zero-
order Part  Unique
a Sharedb  
Paired        
P7FC 19.6 15.7      
Fp2 - Fp1high 16.1 12.2  27.9 3.9  31.8 
P7FC 19.6 17      
P8 - P7low 1 -13.8 -11.3  28.2 2.6  30.8 
Fp2 - Fp1high 16.1 14.8      
P8 - P7low 1 -13.8 -12.6  27.4 1.3  28.7 
Combined        
P7FC 19.6 13.6      
P8 - P7low 1 -13.8 -10.5      
Fp2 - Fp1high 16.1 11.5  35.6 6.7  42.3 
Note. All values are correlations represented as signed percentage of 
variance. 
a Calculated as the sum of part correlations. 
b The difference between the sum of part correlations and the 
proportion of the model is the variance shared between variables. 
c The R2 of the model, converted to proportion of variance. 
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 Results  
 
Female. The stepwise regression included all 3 predictors. P7FC was the first variable included 
(F(1,39) = 9.490, p = .004, R = .442), followed by Fp2 – Fp1high (F(2,38) = 8.864, p = .001, R = .564) 
and finally P8 – P7low 1 was added to the model (F(3,37) = 9.035, p < .000, R = .650).  
Part correlations (see Table 3.17) show that the proportion of variance accounted for by each 
measure is primarily independent. Only 6.7% of the model’s 42.3% variance was shared between the 
measures, the remaining 35.6% was unique and divided amongst the measures equally. The measure 
contributing the highest proportion of unique variance was P7FC (13.6%) but this only contributed 
2.1% more than the lowest, P8 – P7low 1 (10.5%).  
Table 3.18 
Proportion of PID-5 depressivity accounted for by the best FAA, PAA and HFD 
measures when paired and combined in male participants. 
Band 







Paired               
P3FC 5.4 3.9           
Fp2 - Fp1high -21.8 -20.4   24.3 1.5   25.8 
P3FC 2.9 2.4           
P8 - P7low 2 5.4 4.9   7.3 0.5   7.8 
Fp2 - Fp1high -21.8 -21.3           
P8 - P7low 2 2.9 2.3   23.6 0.6   24.2 
Combined               
P3FC 5.4 3.5           
P8 - P7low 2 2.9 1.9           
Fp2 - Fp1high -21.8 -19.9   25.4 2.3   27.7 
Note. All values are correlations represented as signed percentage of variance. 
a Calculated as the sum of part correlations. 
b The difference between the sum of part correlations and the proportion of the model 
is the variance shared between variables. 
c The R2 of the model, converted to proportion of variance. 
 
 Male. Neither PAA nor HFD were reliable in male participants. In the interest of comparing 
the part correlations of male and female participants a combined model was tested (see Table 3.18). 
The part correlations display a similar pattern to those seen in the female model; the majority of 
variance is unique to each measure with a minor amount being shared between them. However, there 
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were no increases in overall variance explained that would suggest that the low initial correlations of 
PAA nor HFD were due to some form of suppression effect. 
 
 Discussion  
 FAA, PAA and HFD all contribute primarily unique variance, in roughly equal quantities. The 
amount of variance shared between these measures is a minority. FAA is the primary focus of this 
research, but these findings suggest that PAA and HFD are worth investigating in greater detail as they 
each appear to be independent of each other. HFD appears to be a stronger predictor of depressivity in 
females than FAA. 
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CHAPTER 4: DISCUSSION 
 
Overview 
 In Chapter 1, the literature on FAA, PAA, HFD and their relationship to depression suggested 
three hypotheses: (1) Alpha asymmetry at F4 – F3 will account for the greatest proportion of PID-5 
depressivity variance in the frontal region; (2) The strongest PAA measure will contribute significant 
unique variance when included in a model with FAA; and (3) HFD will contribute significant unique 
variance when paired with FAA or PAA and when FAA, PAA and HFD are all included in a single 
model. 
 Hypothesis 1 was not supported. F4 – F3 did not account for the most PID-5 depressivity 
variance, instead it accounted for the least. Fp2 – Fp1high was the optimal measure of FAA and the 
only FAA measure that was reliable in both male and female participants. Hypothesis 2 was partially 
supported. The optimal PAA measure was P8 – P7low 1 in female participants. P8 – P7low 1 shared very 
little variance with Fp2 – Fp1high, the contribution of each measure remained almost completely 
unique. However, PAA effects were not reliable in males. Hypothesis 3 was also partially supported. 
P7FC was the optimal HFD measure in female participants. When paired with FAA and PAA the 
variance contributed by HFD remained primarily unique. However, HFD effects were not reliable in 
males. A combined model of all three optimised measures in females showed that the majority of PID-
5 depressivity accounted for was unique to each measure, with a minor amount shared between them. 
Although there were no reliable PAA or HFD findings for male participants a combined model 
appeared structurally similar to that for females but with no increase in the explanatory power of PAA 
or HFD of the type that could have resulted from suppression effects reducing their simple correlations 
with depressivity.  
  The results for FAA, PAA and HFD are discussed in greater detail in the subsequent sections, 
followed by a discussion of the combined effects. In each section, an overview of the results, 
interpretation of the results in relation to prior literature and any implications for future research are 
discussed. After these sections, the limitations of this thesis are discussed and conclusions provided.  
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Frontal Alpha Asymmetry  
 
 Overview of results  
 The strongest correlations for each electrode pair were seen in either the high sub-band, or the 
total band. In cases where the total band was the strongest, the high sub-band was always the next 
strongest. In female participants, Fp2 – Fp1high accounted for the largest proportion of variance. The 
total band was the only other band that accounted for a non-trivial proportion of variance, but this was 
almost entirely shared with the high sub-band. No other homologous pair displayed reliable 
correlations. In male participants, reliable correlations occurred at Fp2 – Fp1high, Af4 – Af3high and F8 
– F7total, and all were negative. Part correlations showed that the proportion of variance accounted for 
within and between electrode pairs was primarily shared, with the part correlations of weaker variables 
reducing to irrelevance when the strongest correlations were included. As Fp2 – Fp1high was the only 
correlate to reach significance in both genders it is the best single FAA measure in this experiment.  
 
 Hypothesis 1 
These results did not support our literature-based hypothesis that the F4 – F3 pair would 
display the best correlations. The results instead show the exact opposite: that F4 – F3 provides the 
worst AA correlations in both genders.  
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 FAA literature 
The main aim of this thesis was to identify the best FAA measure to use in neurofeedback 
protocols targeting depression. The results show that Fp2 – Fp1high is the best FAA measure for that 
purpose. It was the only measure that reached significance in both males and females. This area has 
been identified in EEG studies of depression and anxiety as significant, although results are mixed 
with some positive (Hinrikus et al., 2009; Liao et al., 2013) and others finding null results (Carvalho et 
al., 2011; Gold et al., 2013). In the wider AA literature, significant effects have been found in the 
frontopolar region, particularly in relation to anxiety (Demerdzieva & Pop-Jordanova, 2015; Papousek 
& Schulter, 2002; Smith, Zambrano-Vazquez, & Allen, 2016). Anxiety and depression exhibit a very 
high rate of comorbidity (Lamers et al., 2011) so significant findings for both disorders in the same 
location is not unexpected.  
In support of our frontopolar findings is a wealth of neuroscientific research showing 
relationships between depression and the frontopolar region. The frontopolar electrodes (Fp1, Fp2, 
Fpz) are located over Brodmann area 10, a subsection of the ventromedial prefrontal cortex (vmPFC). 
Studies of lesions in the vmPFC suggest that it may be causally involved in depression (Koenigs & 
Grafman, 2009; Ritchey, Dolcos, Eddington, Strauman, & Cabeza, 2011). Other findings include 
reduced oligodendroglial activity (Hayashi et al., 2011), decreased activity during conversation (Takei 
et al., 2014) and abnormal fatty acid composition (Tatebayashi et al., 2012) in the frontopolar area of 
depressed individuals. These findings all point to the frontopolar region as playing a significant role in 
depression and reduce the odds of our finding being spurious. Our F3 – F4 results may be due in part 
to our use of the statistically refined PID-5 depressivity trait measure and it is possible that other 
measures (e.g. PID-5 anxiety, clinically assessed depression) might show stronger relationships with 
F3 – F4. 
 The direction of correlation observed in the frontopolar region was not expected. Previous 
research has displayed negative correlations between alpha asymmetry and depression, indicating 
hypoactivity in the left hemisphere. Male participants followed this pattern, but female participants in 
this study displayed positive correlations between asymmetry and depressivity. Interpreting this is 
difficult as the frontopolar area is under-investigated. The simplest explanation is that it’s positive 
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because there is a true positive correlation there. The main area from which negative correlations are 
reported in the literature is F4 – F3, which was also negative in the current study. However, the 
strongest sub-band in F4 – F3 only accounted for 1.1% of PID-5 depressivity variance, which makes 
the finding high unreliable. Differing directionality has also been observed between genders in other 
studies (Miller et al., 2002). With the midfrontal area following the direction of previous studies and 
differential effects observed in genders previously, it is reasonable to take the positive correlation at 
face value.  
 
Implications for future research  
There are several important implications for frontal alpha asymmetry stemming from this 
thesis. The difference between sub-bands was quite distinct in our findings, suggesting that the use of 
total alpha band analysis is likely to miss key features. The electrode search conducted here has shown 
that important results may be found in areas not often analysed, implying that the individual analysis 
of a wider range of homologous pairs is warranted as is comparison of their relations among different 
well-constructed trait measures and/or distinct diagnostic categories. The opposing direction signs 
between genders strongly back the a priori separation of genders when it comes to data analysis, 




Page - 62 
Parietal Alpha Asymmetry  
 
 Overview 
 In females, the strongest measures for each pair were found in the low 1 sub-band. Of those, 
only P8 – P7low 1 was reliable. Part correlations showed that P8 – P7low 1 contributed high unique 
variance compared to other sub-bands whose part correlations reduced to trivial values. Therefore P8 – 
P7low 1 was chosen as the best correlate for females. There were no reliable correlates for male 
participants, so none moved forwards.  
 
PAA literature  
These findings fit in with previous AA literature and wider neuroimaging literature. PAA has 
previously been linked to depression status (Kentgen et al., 2000; Tement et al., 2016) and also to 
lifetime depression status (Stewart et al., 2011). Gender and comorbid anxiety also appear to have 
considerable influence (Bruder et al., 1997; Kentgen et al., 2000; Tement et al., 2016). In the wider 
literature, functional connectivity models of depression have found the temporoparietal area to be 
important (Zeng et al., 2012). This area is also thought to be involved in emotional arousal with 
depressed patients exhibiting right lateralised hypofunction (Moratti, Rubio, Campo, Keil, & Ortiz, 
2008). 
 
Implications for future research  
 Prior studies have focused primarily on FAA. The present results support the claims made by 
Stewart et al. (2011) that the parietal region is understudied. Although PAA findings were not as 
strong as those in the frontal region, they were reliable. The correlations occurred in the opposite 
direction to those seen in FAA, in a different sub-band, and only in females. These differences indicate 
that the parietal region is worth researching in the future. Furthermore, with reliable correlations 
observed in both frontal and parietal regions, research targeting occipital and temporal areas may well 
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be worth undertaking.  As with FAA, PAA produced quite different results between females and 
males. 
 
Higuchi’s Fractal Dimension 
 
 Overview of results  
 There was a high level of intercorrelation between HFD scores across all electrode sites, 
meaning that HFD at one electrode was very similar to HFD at any other electrode. This indicates that 
HFD may be a global phenomenon, with little heterogeneity between electrode sites. Given that 
complexity is likely to arise from interactions between multiple areas, this is not surprising. In female 
participants HFD reliably accounted for a sizable proportion of depressivity variance at every 
electrode site. HFD at P7 was selected as the best electrode, though P3 had an almost identical level of 
correlation. Part correlations revealed that the majority of variance was shared, further reinforcing the 
plausibility of HFD as a global change. As with PAA, HFD was not significant in male participants.  
 
HFD literature  
The findings of this thesis fit well with other studies, which have found full channel HFD to 
reliable correlate with depression (Akar et al., 2015; Bachmann et al., 2013; Hosseinifard et al., 2013). 
Unlike the chequered findings for alpha asymmetry, HFD has seen consistent correlations with 
depression.  
 
Implications for future research 
The elevated level of intercorrelation observed between HFD at all electrodes is of high 
interest because it implies that HFD is a global measure. If HFD at one electrode is roughly equivalent 
to HFD at any other electrode it would be very useful for neurofeedback protocols as specificity of 
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location would be unimportant. It also brings up the possibility of a global increase in EEG complexity 
in females that correlates with depressive symptomology, the neural mechanisms underpinning that 
complexity could be useful clinically. However, our data provide no reason to assume that HFD could 
be used for neurofeedback in males. 
 
Additivity of FAA, PAA and HFD 
 
 Overview of results 
 The strongest measures from FAA, PAA and HFD contributed high levels of unique variance 
to the combined model in females. Comparatively little variance was shared. These findings indicate 
that each of the measures is identifying distinctive features and they are not all just different measures 
analysing the same mechanisms. Of the three, HFD (P7FC) was the strongest individually, follow by 
FAA (Fp2 – Fp1high) and then PAA (P8 – P7low 1). However, FAA was the only measure, which was 
reliable at a single site in both genders, while PAA and HFD were specific to females.  
 A male combined model was tested to see if the pattern of part correlations seen in female 
participants (primarily unique variance contributed by each measure) would also be present in male 
participants. The same pattern was seen in male participants. The finding is unreliable as both PAA 
and HFD were weak. There was no evidence that the low values for either PAA or HFD in males were 
due to a suppression effect and so, although weak, the additivity in males appears to be qualitatively 
the same as in females. 
 
 Hypothesis 2 
 The hypothesis for PAA predicted that the majority of variance accounted for by PAA would 
be unique from that accounted for by FAA. The results supported this hypothesis. When P8 – P7low 1 
was paired with Fp2 – Fp1high, very little variance was shared between them and the clear majority was 
unique to each measure. However, this only applies to females. 
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 Hypothesis 3  
 The hypothesis for HFD predicted additivity with both PAA and FAA. The results support this 
hypothesis. When paired with either measure only a negligible portion of depressivity variance was 
shared, with the vast majority remaining unique to the individual measures.  However, this only 
applies to females. 
 
 Literature 
 To my knowledge these measures have not been directly compared before. The findings of 
this thesis suggest that the relationship between alpha asymmetry and depressive symptomology is 
likely more localised than often suggested in the literature. While some researchers analyse 
homologous pairs on their own merits (Gold et al., 2013; Jaworska et al., 2012; Segrave et al., 2011), 
others collapse scores across homologous pairs (Blackhart et al., 2006; Nelson et al., 2012). The 
present results suggest that there are localised effects that may be missed if electrodes are averaged 
hemispherically.  
 The additivity seen between the optimised measures is of interest. FAA, PAA and HFD shared 
very little variance between them, the majority of variance accounted for by each measure was unique. 
If these measures were all representing the same underlying mechanisms we would expect them to 
share a lot of variance. The lack of shared variance instead suggests that the mechanisms involved are 
different for each measure. Additivity between FAA and PAA is further evidence against the practice 
of collapsing data hemispherically mentioned in the preceding paragraph; these are two localised 
measures conveying almost entirely unique information. Unlike the localised effects seen in the AA 
measures, changes in HFD appear to be global and unique from the other measures. Overall it seems 
that all three measures are unique, alpha asymmetry has localised effects while HFD is more global.  
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 Implications for future research 
 The additivity seen between measures is particularly interesting. Previous studies have 
focused on the notion of differences at the hemispheric level, but the findings of this research suggest 
otherwise. Frontal and parietal findings exhibited opposite direction in correlation, showing that 
hemispheric differences are not consistent across the entire brain. The additivity of FAA and PAA 
provide further evidence the link between alpha asymmetry and depression is more localised than 
suggested in the literature. Future research would likely benefit from including both frontal and 
parietal asymmetry due to their distinct relationships with depressivity.  
 Unlike alpha asymmetry these results suggest that increases in depressivity involve an 
increase in HFD at every electrode in females. While alpha asymmetry appears to be localised, this 
does not appear to be the case with HFD. The additivity of FAA, PAA and HFD measures is evidence 
that both global and localised electrophysiological changes occur with depressive symptomology, 
suggesting that there may be several different biological mechanisms at play. Future research 
investigating these mechanisms, the relationships between them and the role of other 
electrophysiological measures would be invaluable to the understanding of depression.  
 
Implications of the Current Results for Neurofeedback 
The findings of this thesis challenge the methodology used in neurofeedback protocols. 
Recent neurofeedback experiments targeting depression have used scores obtained from the midfrontal 
(F4 – F3) region (Jesulola, Sharpley, Bitsika, Agnew, & Wilson, 2015; Mennella, Patron, & Palomba, 
2017; Peeters, Oehlen, et al., 2014; Quaedflieg et al., 2016; Wang et al., 2016). The results of this 
thesis (albeit with a low number of participants) failed to find a reliable correlation between the 
midfrontal pair and depressivity, suggesting that the F4 – F3 pair may not be an ideal target.  
The identification of Fp2 – Fp1high as the best FAA measure carries several implications for 
neurofeedback. The use of frontopolar electrodes can allow for simplified equipment, easier 
application and increase accessibility of neurofeedback. An EEG headset specifically designed for 
neurofeedback could be streamlined to only record from the relevant electrodes, heavily reducing the 
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number of electrodes needed. These reductions would reduce the cost of such a headset. The 
frontopolar region is not covered in hair, making it the most readily accessible EEG area. Dry 
electrodes are easier to design when hair is not an issue, eliminating the need for electrode gel and 
simplifying the application procedure. Use of dry electrodes would also improve the plausibility of 
self-administration. Cheaper, easier to use equipment is already available for small numbers of frontal 
sites and opens the possibility of wide-scale commercialisation and therefore greatly improved 
accessibility. The application of this kind of neurofeedback is possible now and is not dependent on 
future technological developments.   
 There are some negatives to the use of Fp2 – Fp1. Any neurofeedback protocol using that 
region needs be processing in real time. The frontopolar electrodes are the electrodes most affected by 
eye blinks, introducing the possibility of eyeblink artefacts polluting data. This necessitates the use of 
an automated process that can filter eye blinks effectively. Such a procedure has recently been 
developed in our laboratory but not yet tested in the context of neurofeedback (McNaughton, Personal 
Communication). Another comes from the gender differences seen. As male and female participants 
exhibited opposite sign correlations in the same area (and differ in relation to PAA and HFD) 
neurofeedback protocols using Fp2 – Fp1high may need to be gender specific or even tailored to the 




 Multiple testing issues 
 This research took a broad approach to address current issues in AA literature. While it was 
necessary to investigate the differences in eye condition, bandwidth calculation and sub-bands, this 
breadth came at the cost of an increased number of variables. With more variables comes a 
corresponding increase in the chances of false positives and an increase in type 1 error rate. Therefore, 
there is a clear possibility that the results found here are spurious and so replication is needed.  
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 Although there are methods that aim to correct for increase type 1 error rate, no such method 
was applied in this study. Corrections, such as the Bonferroni correction, help reduce type 1 error rate, 
but also increase the odds of discarding a true positive (increase type 2 error rate). The level of 
significance typically seen in AA experiments is low enough that a true positive would almost 
certainly be ruled out if corrections were applied to this study. Even if correction was applied and 
findings remained significant, the need for replication would not be diminished due to the 
inconsistency of findings in the literature. Therefore, correction was not applied as it would cause an 
unacceptable increase in type 2 error and would do little to improve the strength of the study. 
Replication in a completely new larger sample of participants and using focussed hypotheses based on 
the current results, not altered p-values, is needed to fortify these findings.  
 
 Sample size and homogeneity 
 The demographics of our sample, as well as the sample size are also limiting factors. The 
participants are relatively homogenous: young university students. As with any restricted sample it 
would be unwise to assume that the findings generalise to other populations. Further, a narrowing of 
the variance range may have suppressed detection of correlations (and so potentially account for the 
poor F3 – F4 results). The small sample size further compounds these issues. This thesis used a large 
number of variables and split the participants by gender which further reduces the power of the 
findings.  
 This thesis aims to identify something that is practically useful in the future. To be useful it 
must have a reliable effect size in small sample sizes, ideally at the individual level. If the effect is not 
observable at our sample size (66) then it’s unlikely to be clinically useful. The most effective way of 
addressing the limitations of this study is replication in future research. No single study is likely to 
provide insurmountable evidence, especially not in a field with a history of inconsistent results. 
However, if these effects are practically useful they will also need to be robust enough to be seen in 
other samples. Replication is essential for validating these results and is absolutely required if this is to 
ever be clinically useful.   
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 Specificity to depression 
 This study only analysed the relationship between the various measures and PID-5 
depressivity. It is possible that these measures are not depression specific, but are more generalised in 
nature. Anxiety, neuroticism, clinical depression scales, or some underlying trait that affects all three 
may better correlate with these measures. While the results of the present study demonstrate a 
correlation, future research is needed to determine the specificity of the relationships identified here if 
the measures were to be used as biomarkers. However, it should be noted that a lack of specificity 
would be more an advantage than a problem for use in neurofeedback. 
 
Conclusions 
 Neurofeedback protocols targeting depression have used alpha asymmetry in the midfrontal 
electrodes (F4 – F3) as an index of depression, seeking to alleviate symptomology through 
manipulation of this asymmetry. This is based on a body of work which identifies left frontal 
hypoactivity (greater relative left alpha power) as a correlate of depression, primarily in the midfrontal 
area. However, research linking alpha asymmetry to depression has not always been consistent. This 
inconsistency prompted the research in this thesis, aiming to identify the optimal alpha asymmetry 
index for a neurofeedback protocol.  
 The results of this present experiment suggest that the best frontal alpha asymmetry measure 
to use in a neurofeedback protocol is Fp2 – Fp1high. The findings show mixed support for the theory of 
left hypoactivity (relatively greater left alpha power) being linked to depressive symptomology. 
Correlations were generally positive in female participants and negative in male participants. This 
suggests right hypoactivity in females, and left hypoactivity in males. However, the midfrontal 
electrode did display negative correlations in both genders though these did not reach significance. 
This may indicate that the left hypoactivity observed in other research is localised, varying across the 
frontal region.  
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 Further support for the possibility of localised effects in alpha asymmetry were the findings 
regarding parietal alpha asymmetry. Lateral parietal asymmetries typically displayed an inverse 
direction of correlation to their frontal counterparts, a finding observed previously by Stewart et al. 
(2010). The majority of variance accounted for by parietal asymmetry was unique and not shared with 
frontal asymmetry in females. If AA effects were global, we would expect that asymmetry in any pair 
would display primarily shared variance with other pairs. Instead we have mainly unique variance, 
with differing signs and different sub-bands by region within the same participants, a pattern of 
findings more consistent with localised effects occurring in different regions within the alpha 
bandwidth.  
 In addition to alpha asymmetry, HFD was also analysed in this study. HFD had previously 
been found to correlate significantly with depression across several different studies and has also been 
applied to neurofeedback protocols before. Our findings support previous studies correlating HFD 
with depression. Results also suggest that, unlike alpha asymmetry, HFD is a global phenomenon with 
all channels demonstrating high levels of intercorrelation and shared variance.  The variance 
contributed by HFD is distinct from both FAA and PAA, supporting our original speculation that 
because it analyses a different kind of information HFD would be additive to alpha asymmetry. 
 To summarise: Fp2 – Fp1high is the frontal AA measure that best correlates with PID-5 
depressivity. As it is the best AA measure it is also the measure best suited for neurofeedback due to 
its consistency across genders. P8 – P7low 1 was the strongest parietal AA measure in females, though 
there was no significance in any parietal channels for males. HFD was likewise significant only in 
females, but was significant in every channel with P7FC being marginally stronger than others. All 3 
measures are additive, with most of their variance being unique and this pattern was also present in 
male participants.  
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Stop Signal EEG and Personality 
 
(Principal Investigator: Professor Neil McNaughton, Department of Psychology, 03-479 7634) 
 
INFORMATION SHEET FOR PARTICIPANTS 
 
Introduction 
Thank you for showing an interest in this project.  Please read this information sheet carefully. Take 
time to consider and, if you wish, talk with relatives or friends, before deciding whether or not to 
participate. If you decide to participate we thank you.  If you decide not to take part there will be no 
disadvantage to you and we thank you for considering our request. 
   
What is the aim of this research project? 
This project investigates how the electrical activity of your brain varies when you are trying to stop a 
response once you have started making one. We are particularly interested in how one specific brain 
rhythm (which appears when stopping and going are in conflict with each other) relates to current 
questionnaires that measure anxiety-related traits. The results should show how the various personality 
trait measures relate to trait variation in the conflict response and should also provide a basis for 
developing a new conflict response scale, extreme responses on which could potentially be used to 
diagnose a specific kind of anxiety disorder. The brain rhythm data will also provide a reference 
population against which clinical groups can be compared in future. 
 
Who is funding this project?  
This project is part of the work funded by a grant to Professor Neil McNaughton and collaborators at 
the University of Otago and the University of Auckland from the Health Research Council of New 
Zealand. 
 
Who are we seeking to participate in this project? 
We are seeking participants who are 18-40 years old, healthy (with no major illness in the previous 30 
days), with no regular use of psychotropic medication in the last 6 months and no use of alcohol in the 
24 hours before testing. You should be willing to receive medical and psychiatric screening interviews 
and undergo a urine test for psychotropic compounds. 
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You will NOT be able to participate in the project because it may involve an unacceptable risk to 
you if have: 
1. Susceptibility to photosensitivity. 
2. A history of seizure. 
3. A history of allergic skin reactions to chemical agents including detergents. 
 
If you participate, what will you be asked to do? 
For the main part of the test, we will record the electrical activity from your scalp, heart and a finger 
during a ten minute rest period and in a “stop signal” task with stimuli delivered on a computer screen 
and through earphones and to which you will make responses using a computer mouse. You will be 
interviewed about your physical and mental health and also be asked to complete several 
questionnaires that measure aspects of your mood and personality. The whole experiment will take 
about three hours. In recognition of the time, inconvenience, and travel costs in attending for testing, 
you will be compensated at a rate of $15 for each hour of attendance.  
 
Preparation for the experiment 
Hair products and natural oils on our scalp make it difficult to record your brain activities. It is 
important to us that you come with a clean scalp. Please avoid using any hair products on the day of 
the experiment.  We recommend that you wash your hair on the day or the day before and avoid using 
a hair conditioner. For participants with glasses, we also recommend that you wear contact lenses if 
possible for your own comfort.  
 
Electrical recording procedure 
You will put on an electro-cap as shown in the picture. We will fill the 
electrodes (small metal discs) attached to the cap with a gel that conducts brain 
signals from your scalp to our recording system. To achieve good recordings, 
we will abrade your skin gently before applying the gel. The electrodes are then 
connected to an amplifier that allows us to record your brain rhythms (EEG). 
We will also attach stick-on electrodes to your body to record your heart activity 
(ECG) and a clip on electrode to an index finger to measures your skin 
resistance/perspiration (GSR). The whole system is regularly tested and passes the current standards 
for connecting electrical equipment to people. 
 
Is there any risk of discomfort or harm from participation? 
There is a risk of allergic skin reaction to the electrode gel and of minor discomfort from the abrasion 
of the skin surface during gel application. Exposure to stimuli on a computer screen has a rare risk of 
inducing seizures in those with or without a history of seizure. If you have a history either of 
photosensitivity or of any form of seizure you should not take part. The person running your electrical 
testing is required to be trained in the procedures for connecting you to the equipment and to have a 
current First Aid Certificate (with training renewed every two years by the New Zealand Red Cross) 
so that they can respond appropriately to any unexpected adverse events that occur during testing. 
 
What data will be collected, and how will they be used? 
Your physical and mental health status, questionnaire scores, and elecgtrical recordings will be stored 
in secure computer databases and will be identified only with your participant number. Any paper 
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records will be stored securely in locked filing cabinets. Health status will be assessed only to exclude 
participants who do not meant the entry criteria. Questionnaire and electrical data will be subjected to 
group statistical analysis to determine general group-wide personality trait relationships and reference 
data. Urine samples, identified only by participant number, will be disposed of by the analysing 
laboratory using their usual procedures and only the qualitative, present/absent, result returned by the 
laboratory will be used for inclusion/exclusion. Data will be stored for 10 years and then deleted. 
 
What about anonymity and confidentiality? 
No identifying data will be recorded. All collected data will be linked only to your participant number. 
All data will be stored securely and accessed only by study personnel. Reporting of the completed 
research will be of aggregated data over all participants and no data will be reported linked to an 
individual participant number. 
 
Can Participants Change their Mind and Withdraw from the Project? 
You may withdraw from participation in the project at any time and without any disadvantage 
to yourself of any kind. 
What if Participants have any Questions? 
If you have any questions about our project, either now or in the future, please feel free to contact 
either:- 
 
Shabah Shadli (Telephone: 03 479 5835) or Professor Neil McNaughton (Telephone: 03 479 7634) 
shabah.shadli@otago.ac.nz   nmcn@psy.otago.ac.nz 
 
This project has been reviewed and approved by the University of Otago Human Ethics Committee (Health: H 
15/005). If you have any concerns about the ethical conduct of the research you may contact the Committee 
through the Human Ethics Committee Administrator (ph 03 479-8256 or email gary.witte@otago.ac.n). Any 
issues you raise will be treated in confidence and investigated and you will be informed of the outcome. 
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Stop Signal EEG and Personality 
 
(Principal Investigator: Professor Neil McNaughton, Department of Psychology, 03-479 7634) 
 
 
CONSENT FORM FOR PARTICIPANTS 
 
1. I have read the Information Sheet concerning this study and understand the aims of this 
research project. 
2. I have had sufficient time to talk with other people of my choice about participating in 
the study.   
3. I confirm that I meet the criteria for participation which are explained in the Information 
Sheet. 
4. All my questions about the project have been answered to my satisfaction, and I 
understand that I am free to request further information at any stage.  
5. I know that my participation in the project is entirely voluntary, and that I am free to 
withdraw from the project at any time without disadvantage. 
6. I am aware that undergraduate students will be present and will carry out some parts of 
the experiment. 
7. I know that as a participant I will undergo electrical (EEG/ECG/GSR) testing, physical 
and mental health screening, and a qualitative urine test for psychotropic drugs and 
complete questionnaires assessing emotion, as listed in the information sheet. I 
understand that I may decline to answer any interview or questionnaire question without 
disadvantage of any kind. 
8. I know that no personal identifying information will be included in the paper records and 
electronic files which represent the data from the project, and that these will be placed in 
secure storage and kept for at least ten years.  
9. I understand the nature and size of the risks of discomfort or harm that are explained in the 
Information Sheet, including the rare risk of computer screen-induced seizures. 
10. I understand that the results of the project may be published but my anonymity will be 
preserved and only group data reported. 
 




Page - 88 
   (Full name) 
 
 
.............................................................................    ............................... 
       (Signature of participant)       (Date) 
 
This project has been reviewed and approved by the University of Otago Human Ethics Committee (Health: H 
15/005). If you have any concerns about the ethical conduct of the research you may contact the Committee 
through the Human Ethics Committee Administrator (ph 03 479-8256 or email gary.witte@otago.ac.n). Any 
issues you raise will be treated in confidence and investigated and you will be informed of the outcome. 
 
